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Abstract 
 As the persistence of inflammatory response can result in harmful effects to the 
organism, nonsteroidal anti-inflammatory drugs (NSAID) have emerged to treat 
inflammatory conditions. Indeed, these drugs represent one of the most widely consumed 
pharmaceuticals due to their anti-inflammatory, analgesic and antipyretic properties. 
Although they are used in acute situations and for minor aches, they are particularly relevant 
in chronic cases. Yet, their chronic consumption is associated with a wide spectrum of 
unwanted effects, including gastrointestinal, cardiovascular, hepatic and renal toxicity. In 
this context, two approaches were established in the attempt of reducing NSAID toxicity: 
the modification of conventional drugs and the development of novel drugs to act on new 
targets. Some of these strategies have already resulted in the commercialization of 
pharmaceuticals, while others are in clinical trials or under development. 
Interestingly, the currently well-described NSAID main mechanism of action – 
inhibition of the prostaglandins (PG) biosynthesis – does not fully explain their adverse 
effects. The investigation of additional mechanisms is crucial to understand how safer 
NSAID can be developed. The hypothesis that the therapeutic and toxic actions of NSAID 
can derive from their relation to cellular membranes has triggered the in vitro assessment 
of NSAID-membrane interactions. Effectively, different studies have shown their ability to 
alter the membrane hydrophobicity, fluidity and structure. Therefore, the study of NSAID-
membrane interactions may enlighten the action of these drugs at the membrane level and 
eventually predict their capability to cause adverse effects in vivo. 
This work aims to assess if diclofenac, one of the most widely consumed NSAID 
worldwide, has the ability to alter biological membranes. This experimental study evaluated 
diclofenac interactions with a membrane model system, DMPC (1,2-dimyristoyl-sn-glycero-
3-phosphocholine) liposomes, and under relevant pH (7.4, 5.0 and 3.0) and temperature 
(37 ºC) conditions that mimic microenvironments where the drug is found after oral 
administration. The evaluation of the drug’s partition was accomplished by derivative 
spectrophotometry; membrane-binding was assessed by a fluorescence titration technique; 
the drug membrane location was determined through steady-state and time-resolved 
fluorescence quenching; the study of the lipid phase transition and fluidity were both 
evaluated using fluorescence anisotropy measurements; and finally, the influence of the 
drug on membrane permeability was verified by a carboxyfluorescein leakage assay which 
encompassed a size-exclusion chromatography followed by steady-state fluorescence 
experiments. It was effectively verified that diclofenac interacts with phospholipid bilayers 
and alters its biophysical properties. The drug’s actions depend on its ionization state, as 
experiments have demonstrated that the protonated form (assessed at pH 3.0) exerts a 
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more relevant effect. Diclofenac location in the membrane was confirmed to be in the 
phospholipid headgroups region at all pH conditions. Overall, its effects on the membrane 
biophysical properties include a decrease of the lipid main phase transition temperature and 
cooperativity, an increase of the fluidity within the phospholipids headgroup region and an 
augmented membrane permeability. 
Finally, gathered results were discussed, firstly, in terms of relevance for 
diclofenac’s therapeutic and toxic effects verified in vivo and, secondly, considering the 
contribution of biophysical studies for responding to the vital need imposed by chronic 
inflammatory diseases: the development of safer and more tolerable NSAID.  
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Resumo 
Uma vez que a subsistência da resposta inflamatória pode resultar em efeitos 
prejudiciais no organismo, os anti-inflamatórios não-esteroides (AINE) surgiram para tratar 
condições inflamatórias. Efetivamente, estes fármacos são amplamente consumidos 
graças às suas propriedades anti-inflamatórias, analgésicas e antipiréticas. Apesar de 
serem usados em casos agudos e para aliviar dores leves, os AINE são particularmente 
revelantes para o tratamento de doenças crónicas. Todavia, o seu consumo crónico estás 
associado a um vasto espectro de efeitos indesejados, incluindo toxicidade gastrointestinal, 
cardiovascular, hepática e renal. Neste contexto, duas abordagens foram estabelecidas 
para tentar reduzir a toxicidade dos AINE: a modificação dos fármacos convencionais e o 
desenvolvimento de novos fármacos para atuarem em novos alvos terapêuticos. Algumas 
destas estratégias já resultaram na comercialização de fármacos mais seguros, enquanto 
outras ainda se encontram em ensaios clínicos ou em desenvolvimento. 
Curiosamente, o mecanismo de ação dos AINE – a inibição da biossíntese das 
prostaglandinas (PG) – não explica os seus efeitos adversos na totalidade. A investigação 
de mecanismos adicionais é crucial para o desenvolvimento de AINE mais seguros. A 
hipótese de que as ações tóxicas e terapêuticas dos AINE podem derivar das suas relações 
com as membranas celulares desencadeou o estudo in vitro de interações AINE-
membranas. De facto, vários estudos mostraram a capacidade dos AINE em alterar a 
hidrofobicidade, fluidez e estrutura das membranas. Portanto, a avaliação das interações 
dos AINE com membranas pode elucidar a ação destes fármacos a nível membranar e 
eventualmente prever a sua capacidade de causar efeitos adversos in vivo. 
Este trabalho visa avaliar se o diclofenac, um dos AINE mais utilizados 
mundialmente, é capaz de alterar as propriedades biofísicas das membranas biológicas. 
Este estudo experimental avaliou as interações do diclofenac com um sistema mimético 
membranar, lipossomas de 1,2-dimistroil-sn-glicero-3-fosfocolina (DMPC), e em condições 
de pH (7.4, 5.0 e 3.0) e temperatura (37 ºC) relevantes que mimetizam os microambientes 
em que o fármaco se encontra após administração oral. A avaliação da partição do fármaco 
foi executada por espetrofotometria derivativa; a ligação à membrana foi avaliada através 
duma técnica de titulação fluorescente; a determinação da localização membranar do 
fármaco foi feita por medições de desativação de fluorescência e tempo-de-vida resolvidos 
no tempo; estudos relativos à transição de fase e à fluidez do lípido foram ambos obtidos 
por medições anisotropia; e finalmente, a influência do fármaco na permeabilidade 
membranar foi verificada por um ensaio de libertação da carboxifluoresceína que envolveu 
a execução de uma cromatografia por exclusão de tamanho seguida por medições de 
fluorescência. Foi efetivamente verificado que o diclofenac interage com bicamadas 
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fosfolipídicas e altera as suas propriedades biofísicas. As ações do fármaco dependem do 
seu estado de ionização, visto que vários ensaios demonstraram que a sua forma 
protonada (aqui estudada a pH 3.0) exerce um efeito mais relevante. A localização do 
diclofenac na membrana foi confirmada ser na região das cabeças polares dos fosfolípidos. 
Além disso, os seus efeitos na membrana incluem um decréscimo da temperatura e 
cooperatividade da transição de fase principal do lípido; um aumento da fluidez na zona 
das cabeças polares dos fosfolípidos e ainda uma permeabilidade membranar aumentada. 
Finalmente, os resultados obtidos foram discutidos, em primeiro lugar, 
relativamente à sua relevância para os efeitos terapêuticos e tóxicos do diclofenac 
verificados in vivo e, em segundo lugar, tendo em conta a contribuição dos estudos 
biofísicos para responder à necessidade vital imposta pelas doenças inflamatórias 
crónicas: o desenvolvimento de AINE mais seguros e toleráveis.  
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1. Introduction 
1.1) Nonsteroidal anti-inflammatory drugs (NSAID) 
1.1.1) Inflammation 
Inflammation is an important biological event that occurs as a response of the 
immune system to infection or injury. The inflammatory response is triggered by mediators, 
which include cytokines, vasoactive amines, plasma protein systems and eicosanoids 
(prostaglandins (PG), leukotrienes (LT) and thromboxanes (TXA)). (1) Inflammatory 
processes can be divided into two distinct phases. The acute phase is dominated by 
neutrophils and the influx of monocytes that differentiate into macrophages and it is 
characterized by redness, heat, swelling and pain. The prolonged presence of monocytes, 
macrophages and lymphocytes, along with the proliferation of blood vessels and connective 
tissue, mark the chronic phase. (2, 3) Although these events are generally seen as 
beneficial, once they lead to the removal of pathogenic factors and allow the recovery of 
the tissue’s physiological function, they can also result in a persistent and dysfunctional 
response, originating scarring and loss of organ function. (3) For this reason, anti-
inflammatory drugs (e.g. corticosteroids and nonsteroidal anti-inflammatory drugs) are 
crucial for controlling inflammatory processes. 
 
1.1.2) General characterization of NSAID 
Nonsteroidal anti-inflammatory drugs (NSAID) are a group of pharmaceutical agents 
that provide symptomatic relief from pain and inflammation as a result of their analgesic, 
anti-inflammatory and antipyretic properties. (4) These type of drugs are available over-the-
counter and can be used for minor aches, in cases of acute inflammatory conditions or as 
a therapeutic for chronic inflammatory diseases, such rheumatoid arthritis (RA) and 
osteoarthritis (OA). (5)  
The use of the anti-inflammatory compounds to treat fever and inflammation dates 
from about 3500 years ago. While the identification of salicylic acid (active ingredient of 
aspirin) occurred in the 17th century, the mass production of salicylic acid only began in 
1860. This compound was found to have some unpleasant properties, as it possessed a 
bitter taste and caused dyspepsia. Hence, its improvement gave birth to aspirin as we know 
it today, acetylsalicylic acid (ASA), which was firstly commercialized around 1897. (6) Over 
the time, other NSAID emerged as better alternatives for the treatment of rheumatic 
diseases, considering that ASA implies high dosages that lead to central nervous signs of 
overdose. (4) The first non-aspirin NSAID to be introduced in the market were indomethacin 
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and ibuprofen in the late 60’s. Diclofenac and naproxen followed, with launches in 1974 and 
1976, respectively. These still remain some of the most widely used anti-inflammatory 
drugs. (7, 8) Nowadays, more than 50 NSAID are available in the global market with 
formulations that can vary from tablets to gels and injections. Their individual potencies 
differ and the choice between the many NSAID is usually dictated by their pharmacokinetic 
behaviour and their adverse effects. (5, 9)  
Despite the early widespread use of NSAID, its main mechanism of action was only 
unravelled in 1971. (10) The knowledge of the drugs’ mode of action later contributed to the 
explanation of some of their adverse effects. Due to their inherent toxicity, the effort to create 
safer and better tolerated anti-inflammatory agents stands until today. 
 
1.1.3) Mechanism of Action 
The NSAID mechanism of action was reported by Vane and Piper that demonstrated 
their ability to hamper the prostanoids biosynthesis, specifically through the inhibition of the 
cyclooxygenase (COX) enzyme. (7) 
 
Figure 1 – Eicosanoids biosynthesis pathway: representation of the prostanoids branch (conversion of 
arachidonic acid by COX-1 and COX-2).  
 
The prostanoids include PG and TXA, which are hormone-like lipids that derive from 
arachidonic acid. This fatty acid, released from the membrane phospholipids by 
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phospholipases upon stimulus, is metabolized by the consecutive action of COX and PG 
isomerases and synthases (Figure 1). The prostanoids biosynthesis pathway is not only 
responsible for the inflammatory response, but also regulates tissue homeostasis (e.g. renal 
blood low, gastric cytoprotection and vasodilation), since PG are involved in a wide range 
of processes and present in many different cell types (Figure 1). (3, 9) 
After the discovery of the NSAID mechanism of action, the COX enzyme isoforms 
were defined. While COX-1 was described in 1976, the COX-2 gene was only identified in 
1991. (7) Nowadays, both isoforms are well-characterized and are known to have more 
than 60% of sequence identity. Nevertheless, they possess some significant structural and 
functional differences. (8) These homodimers possess three domains in each subunit: an 
epidermal growth factor, a membrane binding domain and a catalytic domain that contains 
the active sites. Although three high mannose oligosaccharides can be found in both 
isoforms, COX-2 contains a fourth oligosaccharide that is able to regulate its degradation. 
(11) Another relevant structural divergence concerns the COX active site, where the NSAID 
binding occurs. In the COX-2 enzyme the active site channel is larger and more accessible 
due to differences in the aminoacid sequence. The exchange of a valine in position 523 in 
COX-2 for a more bulky aminoacid, isoleucine, in COX-1 at the active site creates a side 
pocket in COX-2 (Figure 2). This aminoacid exchange has implications for the selectivity 
profile of COX inhibitors. (12) 
 
 
Figure 2 – COX-1 and COX-2 structural differences. Taken from (13). 
 
Regarding their functional role, COX-1 is a constitutive enzyme that is involved in 
tissue homeostasis, including gastric cytoprotection, platelet aggregation, renal blood flow 
auto-regulation and initiation of parturition. Differently, COX-2 expression is induced when 
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inflammatory cells are injured or activated by cytokines, such as interleukin-1 and tumour 
necrosis factor-alpha (TNF-), thereby being mainly associated with the production of 
prostanoids in inflammatory conditions. (5) 
In general, conventional NSAID inhibit both COX-1 and COX-2 in a variable degree. 
While the anti-inflammatory action of the drugs are mainly related to their inhibition of COX-
2, the blockage of COX-1 is more likely to be the cause of unwanted effects, particularly at 
the gastrointestinal (GI) level. This concept triggered the development of the selective 
inhibitors of COX-2 (coxibs). Even though these drugs are presently commercialized, their 
launch was quite controversial (5) – as it will be discussed in section 1.1.5. 
In sum, the NSAID therapeutic properties result from the inhibition of prostanoid 
biosynthesis through the COX pathway. In particular, its anti-inflammatory action is mainly 
associated with the decrease of PG that amplify the inflammatory processes. Also, it can 
also be attributed to their oxygen radical scavenging capacity that decreases tissue 
damage. Their analgesic effects occur by decreasing PG that sensitise nociceptors to 
certain inflammatory mediators. Finally, the NSAID antipyretic effect is achieved by resetting 
the hypothalamic thermo-regulating function, without affecting normal body temperature. (5) 
 
1.1.4) Toxicity 
Despite NSAID huge commercial impact and therapeutic potential, this group of 
pharmaceuticals causes adverse effects that are relevant when extensively used in elderly 
populations and for long periods of time, making them particularly hazardous for chronic 
consumers. (5) Their toxicity relates to the role of PG in physiological processes besides 
their mediation of inflammation (Figure 3). (14) 
 
Figure 3 – Prostaglandins functions and respective adverse effects caused by NSAID-induced inhibition. 
Adapted from (9). 
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GI disturbances are the most common side effect of NSAID and include gastric 
discomfort, dyspepsia, diarrhoea, nausea, vomiting and, in more severe cases, gastric 
bleeding and ulceration. This occurs because PG are very important mediators of mucosal 
defence and repair of the GI tract, therefore their inhibition increases the tract susceptibility 
to damage, meaning that NSAID can frequently cause gastric mucosal injury with risk of 
peptic ulceration and enteropathy. (8, 14) In addition to the systemic effects of NSAID that 
comprise these PG downregulation mechanism, NSAID topical actions are also relevant for 
NSAID-induced GI toxicity. Local action includes the death of epithelial cells by the 
uncoupling of the oxidative phosphorylation, and the decrease of the protective epithelium 
mucosa through the reduction of mucus and bicarbonate secretion. Moreover, NSAID have 
been shown to disrupt the surface-active phospholipid layer on the surface of the gastric 
mucosa, facilitating the penetration of noxious agents on the gastric mucosa. (15) 
NSAID cardiovascular (CV) side effects are also very relevant as they include 
myocardial infarction, hearth failure and hypertension. This can occur because the drugs 
may induce systemic vasoconstriction, particularly in patients with pre-existing heart failure. 
Importantly, the imbalance of the production of the prostanoids PGI2 and TXA2 may trigger 
the occurrence of CV toxicity. The first, produced by endothelial and smooth muscle cells, 
is an antithrombotic and vasodilator agent capable of modulating the interaction between 
activated platelets and the endovascular wall. In contrast, TXA2 is a pro-thrombotic platelet 
agonist and vasoconstrictor biosynthesized in platelets through COX-1. (16) 
Renal adverse effects, like renal ischemia or acute renal failure, may occur in more 
susceptible patients, as the release of PGI2 and PGE2 is increased in cases of renal 
dysfunction, despite the low basal values of PG synthesis rate. Furthermore, patients with 
hypertension often present the release of renal vasodilator PG to reduce renal ischemia; as 
NSAID inhibit this compensatory mechanism, a further elevation in blood pressure is likely 
to occur in response to the increase in both renal and systemic vascular resistance. (16) 
Moreover, asthma attacks possibly caused by the lack of bronchodilating PG have 
also been verified in predisposed patients. (9) Less commonly, skin reactions, central 
nervous system effects, bone marrow disturbances and liver disorders can take place. (5) 
In this context, researchers have been attempting to develop a safer and effective 
NSAID, meaning a drug capable of fighting inflammation and pain causing minimal toxicity. 
An overview of the explored strategies is presented in the next section. 
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1.1.5) Strategies to overcome NSAID toxicity 
Being the NSAID toxicity a topic of growing concern, further mechanisms that could 
be responsible for causing side effects, besides the downregulation of PG, have been 
explored to develop safer treatments. As more insights on the biological actions of these 
anti-inflammatory drugs were gained, the creation of safer and more tolerable NSAID 
emerged through two distinct approaches: the modification of traditional NSAID and the 
development of novel drugs to reach new therapeutic targets. 
 
1.1.5.1) Modification of conventional drugs 
PC-NSAID: One of the first explored subjects concerning the modification of 
conventional NSAID was phosphatidylcholine (PC), an abundant and surface-active 
phospholipid in the gastric mucosa with which NSAID possess a strong ability to associate. 
Indeed, tradition NSAID were shown to alter the lipids hydrophobicity and fluidity (17), 
leading to the destabilization of the protective hydrophobic lining of the GI mucosa. (18, 19) 
The pre-association of NSAID to PC was tested in order to verify if these interactions 
could be prevented, once the drugs binding site becomes unavailable to associate with the 
mucosa’s phospholipids. In preliminary studies using rodent models, a protective gastric 
effect of diclofenac-DPPC (dipalmitoyl-phosphatidylcholine) complex was verified in the 
upper GI tract (20) and a superior anti-inflammatory and analgesic effect of ibuprofen-PC 
vs the unmodified drug was revealed – possibly due to the augmented half-life of the drug 
in the complexed form. (21) Later, various NSAID were evaluated and it was proven that, 
when compared to the equivalent unmodified NSAID: indomethacin-PC presents 
therapeutic effects and reduces GI injury (22); aspirin-PC (specifically PL2200, developed 
by PLx Pharma Inc.) can diminish gastroduodenal ulcers by 70%, while maintaining 
antiplatelet efficacy (23); ibuprofen-PC presents similar bioavailability but reduced 
gastroduodenal injury (significant for patients over 55 years). (21) Even though these drugs 
reveal promising results, only aspirin-PC has been FDA approved; other drug derivatives 
are still under clinical development.  
CD-NSAID: Cyclodextrins (CD) are cyclic oligosaccharides produced from starch 
currently recognized as a relevant class of pharmaceutical excipients. Their solubility can 
be increased through chemical modification that originates, among others, hydroxy-propyl-
β-CD derivatives. Due to their chemical structure (Table 1), they can include whole drug 
molecules within its cavity and consequently augment their solubility and availability. (24) 
For this reason, their application is relevant for poor soluble drugs, since NSAID tend to 
concentrate in its undissolved form in the gastric mucosa, eventually killing its epithelial cells 
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and inducing GI injury. (15, 18) So, NSAID complexation with CD allows the administration 
of drugs’ lower dosages with greater solubility, which may prevent such toxicity.  
A comparative study of ketoprofen and keptoprofen-β-CD exhibited a greater 
solubility, higher bioavailability and also higher anti-inflammatory action for the complexed 
form. (25) Similarly, evidences of increased anti-inflammatory effect were found for 
piroxicam and its inclusion in β-CD. This work also revealed lower gastric damage for the 
CD-piroxicam in animal models. (26) Nevertheless, a study in rats showed no differences 
in terms of renal and hepatic lesions when indomethacin was administered complexed with 
hydroxyl-propyl-β-CD, indicating that there is a similar GI absorption. (27) 
NO-NSAID: the incorporation of chemical moieties in NSAID, allowing the release 
of gastroprotective agents, has been considered as an approach to reduce GI damage. 
Nitric oxide-releasing NSAID (NO-NSAID) have been developed, since NO possesses 
gastric protection capacities that include the promotion of mucus secretion, the increase of 
mucosal blood flow and reduced adherence of neutrophils to the gastric vasculature 
endothelium. (28) NO-NSAID consist in a parent NSAID covalently linked to a spacer which, 
in turn, is associated to a NO-releasing moiety. Many different NO-NSAID have been 
synthetized since the concept emerged and their pharmacological and pharmacokinetic 
properties vary with the type of spacer present in the structure (aliphatic, aromatic or 
heterocyclic). As NO-NSAID are pro-drugs, they suffer a rapid cleaving after oral 
administration, resulting in the separation of the parent drug and the NO-releasing moiety 
attached to the spacer, followed by a progressive metabolism of NO and its slow liberation. 
(29, 30) 
In the last decade, nitroaspirin (NCX-4016) was one of leading NO-NSAID (Table 1) 
and its investigation achieved studies in healthy humans. Although it exhibited low gastric 
toxicity and high potency in the inhibition of platelet activation in comparison to its parent 
drug, the discovery of mutagenicity of one of its main metabolites led to the arrest of its 
development. (31, 32) In vivo studies with NO-NSAID that couple a nitrooxybutyl moiety to 
the parental drug (diclofenac, aspirin and flurbiprofen) have been performed. Coherently, 
all show significantly less gastric mucosal injury following acute and chronic administration, 
while retaining comparable anti-inflammatory activity. (33, 34) Many diclofenac derivatives 
of this kind have also been studied in the past years. Two in vivo studies conducted in rats 
compared both the anti-inflammatory activity and the ulcerogenic effect of the NO-
derivatives with diclofenac and a better gastric tolerability was verified for the novel 
compounds. (35, 36) Gastrosparing effects have been observed with NO-naproxen in both 
animals and humans. In fact, one drug, naproxcinod, has undergone short-term clinical 
studies as a potentially safe treatment option for OA patients. Still, it failed to be approved 
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since FDA acknowledged apprehensions about its CV safety, hence recommending 
additional long term studies concerning this matter. (37) Notwithstanding, since NO plays 
several vital roles in the CV system, including the maintenance of vascular integrity, drugs 
that release this compound are most likely to have cardioprotective effects. (38) 
H2S-NSAID: Hydrogen sulfide (H2S) is a long-known compound but its biological 
effects have only recently been discovered. In fact, it plays an important physiological role 
acting as an endogenous anti-inflammatory agent, being generated in the gastric mucosa. 
It does not only protects the mucosa – promoting its integrity and repair and controlling its 
blood flow – but also regulates the adherence of leukocytes to the vascular endothelium. 
Besides, the reduction of H2S generation has been shown to be a COX-independent 
mechanism of action of NSAID. For these reasons, this gaseous mediator presents itself as 
an attractive candidate to be used as a releasing group from NSAID. (39, 40) 
 
Table 1 – Summary of the strategies employed with example of a novel compound chemical structure. 
 
Pre-clinical studies carried on with H2S-releasing NSAID (H2S-NSAID) per os 
revealed promising results. For ATB-346 (H2S-naproxen), experimental data showed similar 
anti-inflammatory activity to naproxen with reduced gastric damage, including the decrease 
of PGE2 levels, but less gastric damage than the parent compound. (41, 42) Likewise, ATB-
Drug 
complex 
Chemical 
moiety 
Chemical Structure Features of drug complex 
vs parent drug 
PC-
NSAID 
Phosphatidylcholine 
NSAID + 
 
Therapeutic efficacy 
Reduced GI toxicity 
CD-
NSAID 
-Cyclodextrin 
 
CD-piroxicam 
Increased drug solubility 
and bioavailability 
Augmented anti-
inflammatory action 
NO-
releasing 
NSAID 
Nitric oxide 
 
NCX-4016 
Anti-inflammatory action 
Diminished gastric 
ulceration 
H2S-
releasing 
NSAID 
Hydrogen sulfide 
 
ATB-337 
Anti-inflammatory action 
Higher gastrointestinal 
safety 
Lack of CV adverse effects 
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337 (H2S-diclofenac – Table 1), revealed similar results: PG synthesis was inhibited by both 
drugs, while dose-dependent haemorrhagic lesions were only found associated with the 
traditional NSAID. (43) Evidence for ATB-343 (H2S-indomethacin) corroborates the GI 
safety of these drugs, as this novel compound significantly reduces both the gastric damage 
and the leukocyte adherence, in comparison to indomethacin alone. (44) Furthermore, the 
co-administration of the unconjugated parent drug with the specific H2S-related group was 
performed to clarify the mechanism of action of these H2S-releasing drugs. Interestingly, 
the gastric-sparing properties of these compounds were not found after their administration 
as separate entities. (42, 43) This may relate to the fact that the conjugated drug exhibits 
enhanced generation of H2S. (43) Indeed, H2S-releasing drugs present favourable features 
to be employed as substitutes of traditional NSAID. Nevertheless, their clinical development 
is still in a premature stage. 
In sum, preliminary evidence supports that PC-NSAID, NO-NSAID and H2S-NSAID 
are promising strategies reducing GI toxicity, while maintaining the drugs’ therapeutic 
efficacy to inhibit pain and inflammation. 
 
1.1.5.2) Novel drugs aiming at new targets 
COX-2 selective inhibitors: the characterization of both COX isoforms led to the 
belief that the inhibition of COX-1 was responsible for NSAID toxicity, while the inhibition of 
COX-2 explained the drugs’ therapeutic effects, since the latter is produced in inflammatory 
conditions. This line of thought was the rationale behind the development of coxibs and the 
idea that sparing gastric COX-1 inhibition had the potential to decrease gastric damage, 
while maintaining anti-inflammatory action, generated great enthusiasm. (5, 8) Hence, a 
fast and intense development of coxibs took place. Celecoxib and rofecoxib were the first 
to enter clinical trials in 1995 and, 4 years later, the first to reach the market. (10) Etoricoxib 
and lumiracoxib are part of the second generation of coxibs. Notably, these drugs had a 
great socio-economic impact as they generated high volumes of sales. (45) 
Although these compounds effectively benefit over GI toxicity, they still interfere with 
some COX-2 dependent PG, namely PGI2 which is cardioprotective. This explains the 
increased risk of CV disturbances for these drugs and why they are not indicated for patients 
with ischemic heart disease or cerebrovascular disease. (16) In 2004, rofecoxib was 
voluntarily withdrawn from the market, after the observation of significant incidence of CV 
hazards. Later, the sale of lumiracoxib and valdecoxib was also suspended due to their 
hepatic and dermatological toxicity. (12) Yet, as no increased risk of CV thrombotic events 
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was evident for celecoxib and etoricoxib, they remain commercialized and are valuable 
options for patients with pre-existing gastric damage. 
Dual COX-LOX inhibitors: Leukotrienes (LT), a paracrine hormone that act as 
complementary mediators of inflammation, is metabolized in the arachidonic acid pathway 
by the lipoxygenase (LOX) enzyme (Figure 4). (46) LOX are lipid peroxidising enzymes that 
work as dioxygenases. Three known isozymes belong to this group: 5-, 12- and 15-LOX. 
The best characterized and thought to be the most biologically relevant is 5-LOX. (47) 
Taking in consideration the pro-inflammatory profile of LT and prostanoids, it is expected 
that a drug capable of inhibiting the generation of both types of molecules will not only 
present fewer side effects but also an improved anti-inflammatory activity. (47, 48) 
Numerous and diverse molecules have been synthetized to act as dual COX/LOX inhibitors 
over the years. Some of the studied classes of compounds include pyrazolines, reported to 
have moderate to good in vitro inhibiting activity (49); derivatives of phenylpropenoic acids, 
from which the synthetic analogue NNU-hpda (2-(4-hydroxylphenyl)-3-(3,5-
dihydroxylphenyl)pro-penoic acid) stands out for having a potent inhibitory effects on the 
production of PGE2 and LTB4 and presenting a better toxicity profile than most NSAID (50); 
ASA analogues, which were found to be more potent anti-inflammatory agents than aspirin 
and both were devoid of any gastric ulcerogenicity (51); rofecoxib derivatives, from which 
two furanones with optimal COX and LOX inhibition presented higher anti-inflammatory 
activity than the reference LOX inhibitors and moderate analgesic activity. (52) 
Licofelone, another novel dual COX/LOX inhibitor agent, presented note-worthy 
clinical results. Vidal et al. showed the compound’s in vivo ability to inhibit both COX-2 and 
LOX-5 protein expression in vascular lesions, attenuate PGE2 and inhibit LTB4 generation 
in neutrophils. (53) Relatively to indomethacin, licofelone demonstrated a longer duration of 
action, higher effectiveness, reduced gastric ulceration and prevention of NSAID-related 
increase of LT levels. (54) When assessed as a treatment for OA, the drug proved similar 
effectiveness as naproxen. (55) Currently, phase III trials have been successfully completed 
for licofelone. Results revealed comparable efficacy to traditional NSAID and general 
tolerability (56), avoiding the downside of coxibs. (53) Hence, while many dual COX/LOX 
inhibitors are in early development stages, licofelone gathers all the conditions to be 
commercialized in a near future. 
mPGES inhibitors: the microsomal prostaglandin E synthase 1 (mPGES-1) acts 
down the COX enzyme in the prostanoid biosynthesis pathway (Figure 4), converting PGH2 
into PGE2, which is the most important PG involved in inflammation, fever and pain. 
mPGES-1 is induced by pro-inflammatory cytokines and growth factors. What makes this 
target better than the COX enzyme is the fact that it is downstream in the pathway, 
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suppressing only PGE2 and no other physiologically important prostanoids, thus avoiding 
adverse effects. This synthase has been proposed as a drug target in 1999, but the process 
of bringing drugs to the market has been very slow. (57) 
Nevertheless, potent compounds with good selectivity have been recently reported. 
(58-60) Some demonstrated a reduction in the biosynthesis of PGE2 both in vitro (59, 60) 
and in vivo (59), due to the upregulation of PGI2 and PGF2. The most potent studied 
compound (PF-4693627) was found to be orally active and assays using naproxen as a 
reference revealed a good combination of in vitro cell potency, pharmacokinetic, in vivo 
efficacy (using the air pouch model of inflammation) in addition to an attractive synthesis. 
For these reasons, it was selected as a clinical candidate for the treatment of inflammation 
caused by OA and RA. (58) Presently, the most advanced research belongs to Glenmark 
Pharmaceuticals Ltd. that has completed preclinical studies and filed for Phase 1 human 
trials with the molecule GRC 27864. (61) This is a potent, selective, and orally bioavailable 
mPGES-1 inhibitor, currently developed in the pursuance of an effective and safe therapy 
for chronic inflammatory disorders, such as RA and OA. (62) 
Anti-TNF agents: other anti-inflammatory agents have been explored as potential 
solutions to relief the burden of chronic inflammatory diseases. Since TNF- is one of the 
most relevant pro-inflammatory agents, it has been indicated as a target for novel 
therapeutics. Actually, some protein bases injectables, like etanercept, infliximab and 
adalimumab, have already been successfully introduced in the market – all of them are anti-
TNF- monoclonal antibodies that ground their effects on the scavenging of the cytokine. 
(6) Recently, an oral drug that binds and neutralizes TNF (AVX-470) has been approved as 
safe and tolerable under clinical trials for a long-term treatment of patients with active 
ulcerative colitis. (63) One study indicates that anti-TNF- therapy reduces small bowel 
damage and have a gastroprotective effect, although a wound-healing effect remains 
undefined. (64) Overall, anti-TNF agents are strong candidates to replace NSAID, 
particularly in more vulnerable patients. 
Glucosamine hydrochloride: glucosamine is relevant for the alleviation of arthritic 
symptoms, since it is a glycosaminoglycan precursor – one of the major components of 
cartilage. Glucosamine hydrochloride (GS-HCl) has revealed the ability to inhibit COX-2, 
possibly by hampering N-glycosylation or enabling the protein turnover during translation. 
(65, 66) Still, few works prove its efficacy for the treatment of inflammation. In 2013, in vitro 
and in vivo experiments assessed the effects of GS-HCl alone, indomethacin alone and the 
conjugation of both. The decrease of TNF- stimulated by COX-2, the anti-arthritic efficacy 
and gastric sparing effects were all significantly superior when both compounds were 
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administrated. (66) Briefly, GS-HCl presents an interesting strategy but still has a long way 
to go to be viewed as a possible alternative to traditional NSAID. 
 
Figure 4 – Inflammation induction by the arachidonic acid pathway (lLT and PG). The targets inhibited 
by novel drugs are indicated in the scheme. 
 
In conclusion, the development of coxibs did not solve the NSAID toxicity issue, but 
contributed for the intensification of the research for safer drugs. Among novel molecules 
under investigation, the dual COX/LOX inhibitor licofelone has proven to be the most likely 
to reach the market in first place, as well as the mPGES-1 inhibitor from Glenmark 
Pharmaceutical Ltd. 
 
1.2) NSAID-membrane interactions 
1.2.1) The importance of drug-membrane interactions 
The analysis of drug-membrane interactions has emerged as a branch of the study 
of NSAID mechanisms of action. Although the hampering of the prostanoid biosynthesis is 
a crucial action of NSAID, it does not fully explain their pharmacologic and toxic effects. 
Lichtenberger et al. were the first to suggest that both beneficial and deleterious effects of 
NSAID could arise from its interaction with membranes, in particular with phospholipids. 
(67) 
In fact, there are several reasons that rationalise the importance of these 
interactions. First of all, after entering the organism drugs have to be absorbed, distributed, 
metabolized and even eliminated, and these steps require the interaction with biological 
membranes. These processes are especially relevant for NSAID since they have an 
intracellular and membrane target – COX enzymes can be found at the endoplasmic 
reticulum or by the nuclear envelope (11) – and also because they are frequently 
administered orally. Secondly, although pharmacological actions may occur through the 
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association to proteins (e.g. receptors, transporters or enzymes), the relationship between 
drugs and lipids may induce biophysical alterations of the membranes that in turn modify 
protein conformation and alter their activity. In other words, by influencing the membranes’ 
structure, drugs may indirectly modulate protein location and function and ultimately change 
cell signalling and gene expression. In this context, lipids have gained more attention and 
the recognition of their central role in cellular events and certain pathologies has led them 
to be considered novel drug targets. (68) 
As the behaviour of drugs in membranes is highly conditioned by their 
physicochemical properties, for instance their lipophilicity and pKa, NSAID will presumably 
have a strong association with membranes since they are mostly weak acids and 
amphiphilic molecules. (68, 69) On the other hand, drug-membrane interactions also 
influence the drug itself by altering their diffusion, binding and conformation, which can 
culminate in selectivity, efficacy and toxicity changes. (70) In fact, studies with analgesic 
drugs have demonstrated that interactions with lipids can influence a drug’s 
pharmacokinetic properties and efficacy. (71) Additionally, NSAID-membranes studies have 
revealed that these interactions can be involved with both GI and CV side effects, through 
their topical action on the gastric mucosa and their role in the development of several CV 
pathologies. (15, 72) 
In sum, drug-membrane interactions can influence both membrane and bioactive 
molecules properties. So, the study of these interactions is necessary to understand the 
drugs bioavailability, entrance into cellular compartments, efficacy and to contribute to the 
knowledge of drug-induced toxicity mechanisms. 
 
1.2.2) Biological membranes and cell membrane models 
Biological membranes have a dynamic nature and a complex composition. Many 
fundamental physiological events take place within cell membranes, such as signalling, 
transport, fusion and fission. They act as a selective barrier, protecting the cell from the 
external environment, and defining the cell’s boundaries. (68, 73) Their composition 
consists in a lipid bilayer with linked proteins and carbohydrates. Since they possess a 
highly hydrophobic core and a hydrophilic surface due to the amphipathic nature of the 
lipids, membranes are considered impermeable barriers. In fact, lipids are fundamental for 
the dynamics of the bilayer, besides serving as scaffolds for membrane proteins and 
regulating signal transduction. (74) The main lipid constituents of eukaryotic cell 
membranes are glycerophospholipids, such as PC, phospatidylethanolamine (PE) and 
phosphatidylserine (PS). Among these, PC is the most abundant representing over 50% of 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
18 
 
all phospholipids (75) and for that reason it is frequently selected to mimic cell membranes; 
nevertheless, their composition varies between different cell types. 
The originally proposed fluid mosaic model for the plasma membrane structure, 
which proposed that membranes consisted of dynamic and fluid lipid bilayers with 
embedded proteins (76), has been revisited. The idea of homogeneous membranes has 
been replaced by fluid bilayers with rigid microdomains, frequently referred to as lipid rafts, 
explained by the great variety of lipids present in biological membranes. This heterogeneity 
is essential to maintain all membrane functions. (74) Overall, the cell membrane determines 
a balanced environment and, therefore, any modification of its structure or properties by a 
bioactive molecule may affect its functions and integrity. (75) 
Due to their heterogeneity, biological membranes are considered very complex 
structures. Since this reality is very difficult to investigate at the biophysical level, simplified 
artificial membrane model systems that mimic the natural phospholipid bilayer are 
fundamental to study drug-membrane interactions. (68, 75) The use of protein-free lipid 
membranes, such as micelles, liposomes and lipid monolayers (Figure 5) – the most widely 
used models – allows an easier manipulation of the membrane lipid properties and to focus 
on the interaction between the drug in study and the membrane lipids. (69) Micelles consist 
in a hydrocarbon core and a polar surface with close hydrophilic groups. Besides having a 
simple preparation, their surface and hydrophobicity are easily manipulated. Liposomes are 
closed spherical vesicles with an internal aqueous compartment that consist in one or more 
lipid bilayers. On the other hand, monolayers are formed by amphipathic molecules that 
spontaneously orientate themselves in an interface (e.g. air/water), resulting in a planar 
geometry. (71) 
 
Figure 5 – Model membrane systems: liposomes (A), micelles (B) and monolayers (C). 
 
Biophysical techniques are very useful to understand the processes occurring in the 
membrane, once they enable the assessment of membrane responses to drugs’ presence. 
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There is a large amount of techniques that complement each other for the elucidation of 
biological questions as they provide a detailed image of molecular events. (75) 
 
1.2.3) Studies with NSAID 
Until now, several studies concerning NSAID interaction with membranes have took 
place, as reviewed by Pereira-Leite et al. (68) These works include in vitro studies with the 
above-mentioned membrane model systems, in vitro studies with cell cultures and 
molecular dynamics (MD) simulations. 
 
1.2.3.1) Common models and techniques 
The full evaluation of a drug interaction with membranes is only possible when 
several complementary techniques are employed. Liposomes are the most widely used 
membrane model systems for these in vitro studies and different types of liposomes are 
advantageous for the application of specific techniques. For assays that require a high 
amount of sample material, such as X-ray diffraction, differential scanning calorimetry 
(DSC) and nuclear magnetic resonance (NMR), multilamellar vesicles (MLV) are beneficial. 
However, large unilamellar vesicles (LUV) are more often chosen to assess drug-
membrane interactions for having an identical curvature of cell membranes and being a 
homogeneous sample regarding vesicles size. The determination of NSAID partition 
coefficient (Kp) has been done by derivative spectrophotometry, fluorescence quenching or 
electrophoretic light scattering. Fluorescence experiments have also been useful for 
studying many other parameters: the drug membrane location was assessed by 
fluorescence quenching and fluorescence resonance energy transfer; NSAID effect on 
membrane properties was studied through fluorescence anisotropy; and the influence of 
NSAID on membrane permeability was investigated by performing fluorescence intensity 
measurements. The temperature and thermodynamic parameters of the lipid’s phase 
transition was assessed by calorimetric techniques, namely DSC and isothermal titration 
calorimetry. Methods like the Fourier transform infrared spectroscopy (FITR), Raman 
spectroscopy, NMR and X-ray diffraction have allowed the evaluation of the NSAID 
disturbing effect on the phospholipidic bilayer dynamics and structure. (68) 
 
1.2.3.2) Main conclusions and significance for therapeutic and toxic effects 
To primarily understand NSAID-membranes interactions, their lipophilicity and 
hydrophobicity are determined by the study of the drug partition. The Kp is generally 
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expressed as “logD” and has been established to be between 2.0 and 4.5 at physiological 
pH for NSAID. This indicates a good bioavailability and places NSAID in the class II drugs 
(lipophilic with low solubility and high permeability). (77, 78) When considering NSAID 
transportation across cellular membranes, it is important to contemplate both absorption 
and permeation steps, seen that these drugs are mainly driven by passive diffusion. These 
processes are not only affected by the drugs’ lipophilicity but also by their charge. NSAID 
adopt different ionization states at different pH because they are mostly weak acids. Hence, 
their behaviour differs according to the surrounding microenvironment as demonstrated by 
partitioning studies. While drugs with pKa < physiological pH (e.g. indomethacin and 
acemetacin) have a superior Kp for lower pH (79, 80), drugs with pKa > physiological pH 
(e.g. celecoxib) show no significant differences for partitioning at different pH (81). 
Furthermore, NSAID that are negatively charged tend to interact with the phospholipid 
headgroups, as seen with clonixin, tolmetin and diclofenac (82-84), and drugs in the 
protonated form are able to further penetrate the lipids acyl chains, which has been verified 
for indomethacin, meloxicam and piroxicam at pH 5.0 (85). 
Regarding the drugs’ ability to induce alterations in membrane fluidity and order, 
several studies confirm this hypothesis. In fact, both the lipids’ pre-transition and the main 
transition were found to be affected by acemetacin (86), celecoxib (81), ibuprofen (87), 
naproxen (88) and piroxicam (85), among others, through the decrease of the transitions’ 
temperature and cooperativity. The disruption of the bilayers structural organization at 
different physical states has also been reported. For instance, indomethacin modifies 
membrane heterogeneity (89), which may lead to changes in both protein location and cell 
function, and oxicams-induced membrane fusion. These disordering effects may some 
explain NSAID beneficial effects, including their antioxidant (90, 91) and antitumoral (92, 
93) activity. Indeed, the permeability increase of mitochondrial membrane in presence of 
piroxicam can ultimately cause apoptosis, which may be on the basis of its antitumoral 
activity. (94) Additionally, the inhibition of phospholipase A2 activity by NSAID has been 
demonstrated to occur not only by direct interaction with the enzyme but also through the 
alterations of the membrane structure. (95, 96) 
In contrast, the induction of changes in membranes’ fluidity, permeability and 
biomechanical properties, as verified by both in vitro and in vivo studies, are related to the 
prejudicial action of indomethacin and naproxen on the GI mucosa hydrophobicity and the 
NSAID-induced disruption of the gastric surface-active phospholipids protective layer. (97) 
The anti-inflammatory agents’ cytotoxicity is also explained by their ability to increase 
membrane permeability. (98) Furthermore, naproxen, ibuprofen and diclofenac were shown 
to alter the structure of erythrocytes membranes, which possibly explains CV side effects. 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
21 
 
(88, 99, 100) Also, mitochondrial impairment can be seen as a general toxicity mechanism 
of NSAID. For instance, it can relate to GI topical damage since NSAID are uncouplers of 
oxidative phosphorylation leading to epithelial cell death of the GI mucosa or it can justify 
their hepatic and renal toxicity. (101, 102) In particular, nimesulide was found to be 
distributed across the mitochondrial membrane, interfering with its structure and 
compromising fundamental processes, such as permeability, protein/lipid distribution and 
proteins’ activity. (103) 
The research applied to cell cultures, although less extensively, has corroborated 
the results obtained with the model systems, thus validating them. (68) Finally, it was 
possible to obtain a molecular description of the NSAID-membrane interactions and assess 
the drug location using MD simulations. This field already allowed the evaluation of some 
NSAID partition and provided indications of drugs’ effects dependent of their ionization 
state. (104-106) 
 
1.3) Motivation and aim 
1.3.1) Diclofenac 
Diclofenac, 2-[(2,6-diclorophenyl)amino]phenylacetate (Figure 6), is a widely 
commercialized NSAID due to its anti-inflammatory, analgesic and antipyretic properties. 
This phenylacetic acid derivative is a nonselective COX inhibitor and similarly to other 
NSAID, it leads to the occurrence of GI, CV, renal and hepatic adverse effects. (8, 107, 108) 
This drug can be found in diverse formulations, including ophthalmic preparations, topical 
gels, tablets, rectal suppositories and even for intramuscular administration. (8) Its topical 
application has a potent analgesic action and is thought to minimize toxicity (109); on the 
other hand, its consumption per os, one of the most generally used, is the most concerning 
in terms of side effects. 
 
 
Figure 6 – Diclofenac chemical structure. 
 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
22 
 
Regarding its pharmacokinetics, diclofenac is almost completely absorbed when 
administered orally but after suffering the first-pass effect only about 50% reaches the 
systemic circulation in the unchanged form. At therapeutic concentrations, this NSAID is 
over 99% bound to plasma proteins and its plasma half-life is between 1 to 2 hours. The 
drug can be metabolized into different compounds, including 4’-hydroxydiclofenac (major 
metabolite), 5-hydroxydiclofenac, 3’-hydroxydiclofenac and 4’,5-dihydroxydiclofenac. Its 
excretion occurs in the form of glucuronide and sulphate conjugates through urine and bile 
and less than 1% is excreted in the unchanged form. (110) 
Concerning the drug’s therapeutic effects, diclofenac has been proven to be 
effective in treating OA and RA (111, 112) and a meta-analysis supports that diclofenac 
should remain as a reference medication for OA treatment, since therapeutic doses provide 
a similar efficacy to comparators, which include coxibs, meloxicam, nimesulide and 
etodolac. (113) Its analgesic properties have been confirmed in a trial of acute pain in 
children. (114) Nevertheless, diclofenac’s adverse effects have also been observed in 
several trials. The MEDAL (Multinational Etoricoxib and Diclofenac Arthritis Long-term) 
program revealed that etoricoxib has a similar behaviour to the traditional NSAID 
concerning the incidence of gastroduodenal ulcers (115); yet diclofenac-induced GI 
damage is more prevalent than coxibs-induced GI toxicity. (111, 112, 115) CV risk was also 
demonstrated to be relevant for diclofenac. (115) Moreover, diclofenac chronic users 
commonly presents elevated aminotransferase values, despite the low rates of 
hospitalization due to clinical liver events. (116) The assessment of the hepatic safety of 
celecoxib versus three traditional NSAID showed that diclofenac presented the most 
hepatobiliary and serious hepatic adverse effects, although in low percentages. (117) 
 
1.3.2) Diclofenac-membrane interactions 
Some studies on diclofenac’s interaction with membranes are already available in 
the literature. In general, these works have focused on the diclofenac location within the 
membrane and on its effect in some membrane biophysical properties, such as membrane 
fluidity (Table 2). 
 Firstly, the assessment of the drug partition in egg yolk phosphatidylcholine (EPC) 
was performed at pH 7.4 by 3 different techniques. All revealed concordant results, resulting 
in a Kp of around 1200 ± 100 M-1. At pH 3.0 the obtained Kp was of 26000 ± 3000 M-1, which 
is explained by the fact that the drug’s is below its pKa (3.97) and hence it is in its protonated 
form. The relevance of the drug ionization state is also notable for zeta-potential 
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measurements, where increasing concentrations of diclofenac resulted in a decrease of the 
membrane potential at pH 7.4, but induce no alterations at pH 3.0. (84) 
The investigation of molecular interactions between diclofenac and 1,2-dimyristoyl-
sn-glycero-3-phosphocholine (DMPC) liposomes using several spectroscopic and 
thermodynamic techniques revealed that the drug locates preferentially in the polar 
headgroups of the phospholipids, indicating a closer proximity to the phosphate region. 
(118) Diclofenac’s location at the membrane surface was also studied by Ferreira et al., 
who proposed that the drug was exposed to electrostatic adsorption with the zwitterionic 
headgroups of phosphatidylcholine, and sustained these results with the zeta-potential 
evidence mentioned previously. (84) Suwalsky et al. used both DMPC and 1,2-dimyristoyl-
sn-glycero-3-phosphoethanolamine (DMPE) liposomes as membrane model systems for 
similar purposes and only verified relevant interactions of diclofenac with DMPC. This work 
supported that the lipid hydration allows the insertion of diclofenac into the bilayer which 
leads to perturbations on DMPC structure. (99) So, gathered evidence indicates that the 
drug’s amphiphilic nature results in electrostatic interactions of its negatively charged group 
with the positively charged phosphatidylcholine terminal, while its non-polar side remains in 
the neighbourhood of the hydrophobic acyl region of the lipid. 
 
Table 2 – Summary of diclofenac-membrane studies (selected models, applied techniques and main 
study conclusions). 
 
The conclusions retrieved from the drug location assays contributed for the 
comprehension of results concerning the alteration of the membrane fluidity. Ferreira et al. 
Model Techniques Main Conclusions Ref. 
EPC 
Spectrophotometry 
Fluorescence 
anisotropy 
Zeta-potential 
- Higher partition at low pH 
- ↓ Zeta-potential at pH 7.4 and no 
alterations at pH 3.0 
- Drug location at membrane surface 
- ↑ of membrane rigidity 
(84) 
DMPC, 
DMPE, 
human 
erythrocytes 
X-ray diffraction, 
SEM 
- ↑ of membrane rigidity at lipid fluid 
phase of model membranes 
- Alterations of erythrocytes 
morphology 
(99) 
DMPC 
FTIR-ATR, DSC, 
ITC, FRET 
- Drug located near polar headgroups 
of phospholipids. 
(118) 
Mouse 
splenocytes 
Fluorescence 
anisotropy 
- No evidence of diclofenac-induced 
membrane perturbation 
(119) 
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observed membrane properties alterations in the headgroups region and an increase of 
rigidity of EPC, which is clarified by the interaction of the drug’s carboxyl groups. (84) Similar 
results were seen by Suwalsky et al. when assessing the influence of diclofenac in the fluid 
phase of DMPC. (99) Another study showed that diclofenac lowers the lipid main phase 
transition temperature (Tm) probably due to the modification of the lipid headgroups’ 
hydration that results in changes of this region’s packing density. (118) A work that 
resourced to splenocyte membranes also studied NSAID influence in membrane structure, 
but under the utilized conditions there was no evidence of diclofenac-induced membrane 
alteration. (119) 
Aiming to contribute for the understanding of diclofenac’s perturbations in cell 
membranes, human erythrocytes were also used as a membrane model systems. SEM 
visualizations revealed morphological alterations with increasing concentrations of 
diclofenac. Presumably, this diclofenac action can contribute for its toxicity mechanism by 
reducing blood flow, losing oxygen and ultimately causing tissue damage. (99) 
 
1.3.3) Project aim 
There is ongoing research that aims at launching safe NSAID. However, the 
accomplishment of such goal implies a deeper knowledge on the NSAID mode of action 
and, in that sense, evidence supports that the interplay between the drugs and lipid 
membranes is a mechanism that is worth exploring. Although some novel drugs are 
currently under development, understanding how classical NSAID work is one of the key 
factors for a successful analysis of novel molecules. 
Diclofenac is one of the most consumed NSAID worldwide, yet it presents some 
concerning unwanted effects. The information currently gathered in the literature concerning 
diclofenac’s interaction with membranes essentially describes its effect at physiological pH 
(solely Kp and zeta-potential have been determined at pH 3.0). Even though they provide 
important data on the drug location in the membrane and its influence on the lipid bilayer 
transition phase and order parameters, they do not fully explain diclofenac’s behaviour in 
the organism. Every NSAID is found in acidic environments, including inflamed cells and 
the GI tract. Therefore, the study of the diclofenac’s actions in such conditions is 
fundamental to better understand the causes of both its therapeutic and toxic effects. 
For that reason, the goal of the present work is to study diclofenac’s effect in 
membrane biophysical properties in 3 different pH conditions – physiological (7.4), inflamed 
cells (pH 5.0) and gastric mucosa environment (3.0). Since PC is the most abundant 
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phospholipid of the cell membranes, DMPC liposomes were chosen as membrane model 
system. 
Specifically, this project intends to: 
 Evaluate diclofenac’s partition in DMPC liposomes by derivative 
spectrophotometry; 
 Understand diclofenac’s binding mechanism to the membrane surface 
through fluorescence measurements; 
 Assess diclofenac’s location within the phospholipid bilayer by 
fluorescence quenching; 
 Characterize diclofenac influence on the lipid phase transition and fluidity 
by performing fluorescence anisotropy measurements; 
 Quantify the effect of diclofenac on liposomes permeability through a 
membrane leakage assay; 
 Discuss the influence of medium pH on the interaction of diclofenac with 
biological membranes; 
 Discuss the relevance of diclofenac’s effects on membrane biophysical 
properties for its therapeutic and toxic actions and for the rational 
development of safer drugs.  
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2. Materials and Methods 
2.1) Reagents 
Diclofenac sodium salt was purchased from Sigma-Aldrich (St. Louis, USA). 1,2-
dimyristoyl-sn-glycero-3-phosphocholine (DMPC) was supplied by Avanti Polar-Lipids Inc. 
(Alabaster, USA) and L-α-phosphatidylcholine from egg yolk (EPC) by Sigma-Aldrich (St. 
Louis, USA). The fluorescence probes – TMA-DPH (1-(4-Trimethylammoniumphenyl)-6-
Phenyl-1,3,5-Hexatrienep-Toluenesulfonate), DPH (1,6-Diphenyl-1,3,5-Hexatriene) and 
ANS (1-Anilinonaphthalene-8-Sulfonic Acid) – were supplied by Invitrogen probes (Paisley, 
UK). Sephadex G-25 Medium, 5(6)-Carboxyfluorescein and polidocanol were purchased 
from Sigma-Aldrich (St. Louis, USA). Dimethyl sulfoxide (DMSO) and Ludox (colloidal silica) 
were both obtained from Sigma-Aldrich (St. Louis, USA). Perchloric acid 70 % from Riedel-
de Haën (Seezle, Germany), L-ascorbic acid and monopotassium phosphate from Sigma-
Aldrich (St. Louis, USA) and ammonium molybdate from BDH Laboratory Supplies (Poole, 
UK) were used. 
All experiments were performed under three pH conditions with adjusted ionic 
strength (0.1 M NaCl). Tris HCl buffer (pH 7.4, 0.01 M) was prepared from Trizma base 
supplied by Riedel-de Haën (Seezle, Germany), Acetate buffer (pH 5.0, 0.01 M) from acetic 
acid and Formate buffer (pH 3.0, 0.01 M) from formic acid, both purchased from Sigma-
Aldrich (St. Louis, USA). In all cases, pH was adjusted with NaOH or HCl solutions. 
 
2.2) Drug solution preparation 
Diclofenac’s solubility in water depends on its ionization state (pKa = 3.97 (84)), 
being smaller at more acidic environments, when the drug molecule is protonated and 
neutral. Therefore, solubility tests were performed to determine the smallest amount of 
DMSO necessary to assure diclofenac’s solubilisation with Formate buffer. These studies 
showed that DMSO 2% (V/V) was enough to obtain diclofenac solutions (0-40 µM) at pH 
3.0. To maintain identical conditions for all assays, every sample was prepared with DMSO 
2% (V/V) regardless the pH in study. Despite DMSO ability to alter liposomes properties, 
the amount used in these studies does not significantly modify the biophysical properties of 
DMPC liposomes. (120) 
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2.3) Liposomes preparation 
Liposomes are round-shaped artificial vesicles formed by lipid bilayers that contain 
an aqueous compartment. Their lipid composition (consisting mainly of phospholipids), size 
and surface charge can vary. Liposomes are classified according to their number of bilayers 
in multilamellar vesicles (MLV) and unilamellar vesicles, being the latter categorized 
according to their size in small unilamellar vesicles (SUV), large unilamellar vesicles (LUV) 
and giant unilamellar vesicles (GUV) (Table 3). Liposomes are extensively used as 
membrane models, since they allow mimicking cellular membranes and are easily prepared 
through different methods, including sonication, extrusion, high-pressure homogenization 
and detergent dialysis. In this work, LUV were the chosen membrane model system due to 
their simple preparation method and well-characterized membrane properties, such as their 
size, stability and curvature. (121) 
 
Table 3 – Liposome size classification. 
VESICLE TYPE DIAMETER SIZE 
Small unilamellar vesicles (SUV) 20 – 100 nm 
Large unilamellar vesicles (LUV) > 100 nm 
Giant unilamellar vesicles (GUV) 1 - 100 m 
Multilamellar vesicles (MLV) > 500 nm 
 
Here, LUV were prepared by the thin film hydration method (Figure 7). Firstly, DMPC 
was dissolved in a mixture of chloroform and methanol (3:2, V/V). The organic solvents 
were then evaporated under a nitrogen stream in a rotary evaporator (Buchi R-210 
rotavapor equipped with a heating bath BuchiB-491) at 40 ºC for 20 minutes. The lipid film 
formed in a round bottom flask was hydrated with buffer for 30 minutes at 40 ºC. Throughout 
this time, the dispersion was vortexed generating MLV. Finally, to obtain LUV of a specific 
size, extrusion was performed in a Whitey extruder at 40 ºC using a membrane with a 100 
nm diameter pore size (Whatman® Nuclepore Track-Etched Membrane). Vesicles were 
extruded 15 times to reach the desired size. 
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Figure 7 – Liposome preparation by the film hydration method 
 
 
2.4) Drug partition 
Determining the partition coefficient (Kp) is a simple method to initially understand 
the drug behaviour in the presence of a lipid membrane. This parameter provides 
information on how a given drug distributes between lipid and aqueous phases. Although it 
gives no indication on the solute location in the membrane, it supports the prediction of the 
drug’s pharmacokinetics and pharmacodynamics features and helps to understand its toxic 
and therapeutic profile. (122) 
To estimate the Kp, a partition equilibrium between the lipid and aqueous phases 
must be attained and the drug’s concentration is determined in one or both the phases. 
(123) The Kp is in fact an equilibrium constant given by the ratio of the drug concentration 
in the lipid and aqueous phases (Equation 1): 
𝐾𝑝,𝑥 =
[𝑑𝑟𝑢𝑔]𝑙𝑖𝑝𝑖𝑑
[𝑑𝑟𝑢𝑔]𝑤𝑎𝑡𝑒𝑟
=
𝑛𝑆,𝐿
𝑛𝐿+𝑛𝑆,𝐿
𝑛𝑆,𝐴
𝑛𝐴+𝑛𝑆,𝐴
 ≈  
𝑛𝑆,𝐿
𝑛𝐿
𝑛𝑆,𝐴
𝑛𝐴
 Equation 1 
where nA and nL represent the moles of the aqueous and the lipid phases, 
respectively, and nS,X are the moles of solute in each phase. The expression is simplified 
due to negligible amounts of solute versus the amount of aqueous phase (nA>>>nS,A) and 
because the membrane should not be overloaded with solute (nL>>>nS,L). Also, the lipid and 
aqueous phases amounts are commonly represented by their volumes instead of moles. 
(123) 
The Kp can be determined through several techniques involving or not the physical 
separation of free and “membrane-bound” molecules. Membrane filtration, centrifugation, 
equilibrium dialysis and chromatography are the main approaches used to directly 
determine Kp through the separation of lipid and aqueous phases and subsequent 
quantification of the solute amount in the lipid and/or aqueous phase(s). The main 
disadvantages of these strategies are the incomplete separation of phases and the 
equilibrium perturbation. Spectroscopic techniques, including UV-Vis absorption 
spectrophotometry, fluorescence spectroscopy and electron paramagnetic resonance, as 
well as titration calorimetry and zeta potential measurements, have been also used to 
Evaporation Lipid + 
organic 
solvents 
Multilamellar 
Vesicles (MLVs) 
Large Unilamellar Vesicles 
(LUV) – 100 nm 
Lipid film 
hydration 
Extrusion 
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determine Kp without the separation of lipid and aqueous phases. In these cases, 
experimental measurements are performed with several lipid concentrations and the 
retrieved data are a combination of the free and bound molecules signals. These data 
usually follows a hyperbolic-like dependence on lipid concentration, which is fitted to an 
equation from which the Kp value is calculated. (122, 123) 
 
2.4.1) Derivative spectrophotometry 
In this work, the selected approach to determined Kp was derivative 
spectrophotometry, since methods without phases separation are less laborious and avoid 
the risk of disturbing the partition equilibrium. Spectrophotometry is quite sensitive, meaning 
there is no need to use high solute concentrations that could eventually lead to the drug 
insolubilization. 
Considering the application of the Lambert-Beer law and the definition of Kp 
(Equation 1), the absorbance of a given sample containing a drug and both a lipid and 
aqueous phases can be described by: 
𝐴𝑏𝑠𝑇 = 𝐴𝑏𝑠𝑤 +
(𝐴𝑏𝑠𝑙−𝐴𝑏𝑠𝑤)𝐾𝑃[𝐿]𝑉𝜑
1+ 𝐾𝑃[𝐿]𝑉𝜑
  Equation 2 
Where AbsT, Absw and Absl correspond to the drug absorbance of the total, the 
aqueous and the lipid phases, respectively. [L] represents the lipid concentration (mol/L) 
and Vφ is the lipid molar volume (L/mol). (122) 
The high background signals caused by the presence of LUV prevent the direct 
application of Equation 2 to determine Kp and thus, derivative spectophotometry is applied.  
This method allows the elimination of the background interference of the medium and the 
obtainment of spectra with a better resolution of overlapping bands through the calculation 
of the second or third derivatives of the absorption spectra with respect to the wavelength. 
In this case, the estimation of Kp is given by an equation similar to Equation 2: 
𝐷𝑇 = 𝐷𝑤 +
(𝐷𝑙−𝐷𝑤)𝐾𝑃[𝐿]𝑉𝜑
1+ 𝐾𝑃[𝐿]𝑉𝜑
  Equation 3 
 where DT, Dw and Dl correspond to the derivative intensity obtained from the 
absorbance of the total amount of drug, the drug distributed on the aqueous phase and on 
the lipid phase, respectively. [L] represents the lipid concentration (mol/L) and Vφ is the lipid 
molar volume (L/mol). To determine diclofenac’s Kp, samples with increasing concentrations 
of LUV (0-1000 M) and a fixed concentration of drug (40 M) were prepared and incubated 
for 30 min at 37 ºC to attain equilibrium. After incubation, samples were transferred to a 96-
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well plate and their the absorbance spectrum was traced from 230 to 400 nm, also at 37 ºC, 
in a Synergy HT plate reader (Biotek Instruments, Inc.). 
Kp calculator, an Excel software® developed by Magalhães et al. (122) and Origin 
Pro® were used to mathematically analyse the data and estimate the partition coefficient. 
Kp calculator avoids a time consuming process to obtain and evaluate all of the obtained 
spectra, allowing a quick and complete data analysis. This application automatically 
retrieves the absorbance spectra of the experimental results, along with the first three 
derivatives, when inserting the experimental data (absorbance values in a range of 
wavelengths for all samples). Also, it presents the maximum and minimum values of a given 
selected interval of the derivatives spectra, which are used for the fitting to Equation 3 to 
calculate Kp. 
 
2.5) Drug membrane binding 
A possible mechanism of drug interaction with the membrane is its binding to the 
phospholipid headgroups. This type of association can provide some indications of what is 
happening at the first contact of the drug with cell membranes. To study drug-membrane 
binding, an anionic fluorophore that is capable of sensing the polarity of bio-mimicking and 
biological environments was used. ANS is a fluorescent probe whose fluorescence quantum 
yield and wavelength of maximum emission depend on the surrounding microenvironment. 
(124) Although the probe does not fluoresce in water, its binding to DMPC liposomes 
strongly increases the fluorescent intensity. (125) So, a fluorescence signal decrease will 
be translated as an increase of the drug binding due to the competition between the drug 
and the probe for the liposome surface.  
 
2.5.1) Steady-state fluorescence measurements 
ANS stock solution was prepared in DMSO at high concentration so that the highest 
percentage of DMSO in the samples would not exceed the previously established 2%. 
Samples with a fixed concentration of DMPC (500 M) and 3 concentrations of diclofenac 
(0, 40 and 80 M) were prepared. Before adding the probe, samples were incubated at 37 
ºC for 30 min. Then, steady-state fluorescence emission spectra were measured on a Jasco 
FP-6500 spectrofluorometer (Great Dunmow, UK) using the parameters indicated in Table 
4. The measurements were executed at 37 ºC after consecutive additions of the probe in 
order to assess several ANS concentrations (0 – 65 M).  
 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
31 
 
Table 4 – Parameters used in steady-state fluorescence for the membrane-binding assay. 
Probe ANS 
Temperature 37 ºC 
λex 377 nm 
λem 400-600 nm 
Gain 330 V 
Slits 5 nm 
 
The maximum fluorescence intensity registered for each sample with increasing 
concentrations of ANS was plotted against the respective ANS concentrations. Then, the 
fitting to Equation 4 was made to retrieve the constant binding (K), the cooperativity of the 
binding process (b) and the maximum fluorescence intensity (Cmax). 
[𝐴𝑁𝑆]𝐵 = 𝐶𝑚𝑎𝑥
(𝐾[𝐴𝑁𝑆]∞)
𝑏
1+(𝐾[𝐴𝑁𝑆]∞)𝑏
    Equation 4 
[ANS]B represents the amount of bound-ANS and [ANS]∞ the total amount of ANS. 
 
2.6) Drug membrane location 
The determination of the drug location within the membrane is relevant to further 
understand the drug mode of action. Fluorescence quenching is an indirect method to 
evaluate this, since it allows the assessment of the drug location by the inclusion of a foreign 
compound (fluorescent probe) in the membrane. Importantly, for this type of study, steady-
state fluorescence assays must be complemented with time-resolved lifetime 
measurements to fully understand the drug’s quenching mechanism. 
 
2.6.1) Fluorescent probes 
There are a wide range of fluorescent probes that can be applied to study drug’s 
membrane location. DPH is a popular probe of the membrane interior and it is assumed to 
be oriented parallel to the lipid hydrophobic chains (Figure 8), although it can reside in the 
centre of the lipid bilayer parallel to the surface. (126) TMA-DPH is a derivative of DPH that 
is anchored to the phospholipid polar headgroups due to the presence of a cationic group, 
so it locates in the interfacial region of phospholipid bilayers (Figure 8). (127) 
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Figure 8 – Fluorescent probes location in DMPC bilayers (black). DPH (orange) is usually parallel to the 
lipid chains, while TMA-DPH (green) is near the interfacial region of phospholipid bilayers. 
 
For all fluorescence experiments, TMA-DPH and DPH stock solutions were 
prepared in a chloroform:methanol mixture (3:2, V/V)  and added to the organic solution of 
DMPC, at a proportion of 300:1 (lipid:probe), during LUV preparation. 
 
2.6.2) Steady-state fluorescence quenching 
Fluorescence quenching consists in the ability of a given molecule, termed 
quencher, to decrease the fluorescence intensity of a fluorophore. Quenching assays are 
useful to determine the quencher’s location, since the phenomena takes place when the 
fluorophore and the quencher are close to each other. (128) 
To study diclofenac’s membrane location, samples with a fixed concentration of 
fluorophore labelled DMPC LUV (500 M) and various concentrations of drug (0-100 M) 
were prepared and incubated at 37 ºC for 30 minutes. After incubation, these samples were 
transferred to two 96-well plate (one for fluorescence measurements and another for 
absorbance readings) and the samples fluorescence intensity and absorbance spectra 
(respectively) were gathered on Cytation 3 imaging reader (Biotek Instruments, Inc.) using 
the experimental parameters described in Table 5. 
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Table 5 – Parameters used for steady-state fluorescence quenching assays. 
Probe TMA-DPH DPH 
Fluorescence (T = 37 ºC) 
λex 359 nm 357 nm 
λem 429 nm 429 nm 
Gain 70 
Absorbance (T = 37 ºC) 
λ (start-end) 230-500 nm (1 nm interval) 
 
 
Importantly, to correctly interpret quenching results, the concentration of the 
quencher must be considered as the amount of the quencher present in the membrane 
(Equation 5) and the measure fluorescence intensities must be adjusted concerning the 
drug absorption (Equation 6). 
The first correction is due to the fact that the fluorophores are not soluble in water, 
thus quenching occurs solely in the membrane. So, taken in consideration the quencher’s 
partitioning between the lipid and aqueous phase (Kp), the quencher’s concentration is given 
by: 
[𝑄]𝑚 =
𝐾𝑝[𝑄]
1+(𝐾𝑝−1)(𝑉𝜑[𝐿])
  Equation 5 
Where the amount of lipid phase is estimated using the lipid’s molar volume (Vφ) 
and its concentration ([L]) in the samples. [Q] represents the total concentration of the 
quencher in the sample. (128) 
The corrected fluorescence values must be calculated to eliminate the apparent 
quenching that derives from drug absorption at the excitation wavelength of the fluorophore. 
This adjustment, presented in Equation 5, accounts for absorbance in absence (A0) and 
presence of the drug (AQ). (128) 
𝐼𝑐𝑜𝑟𝑟 = 𝐼 ∗ (
𝐴𝑄
𝐴0
) ∗
1−10−𝐴0
1−10
−𝐴𝑄
  Equation 6 
 
2.6.3) Fluorescence quenching mechanisms 
The quenching phenomena can occur due to different types of molecular 
interactions, namely energy transfer, molecular rearrangements and complex formation, 
which result in different types of quenching – preferably distinguished by lifetime 
measurements. (128) The most relevant types of quenching are presented in this section. 
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Dynamic or collisional quenching: collisional encounters occur between the 
fluorophore and the quencher. This phenomena is described by the Stern-Volmer equation: 
𝐼0
𝐼
= 1 + 𝑘𝑞𝜏0[𝑄]𝑚 = 1 +  𝐾𝐷[𝑄]𝑚  Equation 7 
I0/I, representing the ratio of the initial fluorescent intensity and the fluorescence of 
the sample, is expected to be linearly dependent on the quencher membrane concentration 
([Q]m). KD is the Stern-Volmer constant for this type of quenching, while kq is the bimolecular 
quenching rate constant that indicates the accessibility of the fluorophores to the quencher, 
thus reflecting the efficiency of quenching. (128) 
Static quenching: a non-fluorescent complex between the quencher and the 
fluorophore is formed, being this an important indication on the binding of the molecules. 
Importantly, this event takes place in the absence of a permanent change in the molecules. 
The Stern-Volmer constant for static quenching (KS) is retrieved from Equation 8. 
𝐼0
𝐼
= 1 +  𝐾𝑆[𝑄]𝑚    Equation 8 
Like in the previous case, I0/I has a linear relation with [Q]m. Lifetime measurements 
can characterize each type of quenching as 
𝜏0
𝜏
= 1 is verified for static quenching, and 
𝜏0
𝜏
=
𝐼0
𝐼
  is true for purely dynamic quenching mechanism. (128) 
 
2.6.4) Deviations from linear Stern-Volmer plots 
When there is a large extent of quenching, positive deviations from the Stern-Volmer 
equations can be verified. Two models can describe these deviations: combined dynamic 
and static quenching and the sphere of action model.  
Combined dynamic and static quenching: both mechanisms are involved and 
instead of a linear relation for the fluorescence graphs, there is an upward curvature for high 
membrane concentrations of quencher. Here, the dynamic portion is determined by lifetime 
measurements and the quenching is described as (128): 
𝐼0
𝐼
= (1 +  𝐾𝐷[𝑄]𝑚) ∗ (1 +  𝐾𝑆[𝑄]𝑚) Equation 9 
Sphere of action model: there is an apparent static component because the 
quencher is adjacent to the fluorophore at the moment of excitation. The phenomena is 
described by: 
𝐼0
𝐼
= (1 +  𝐾𝐷 ∗ [𝑄]𝑚) ∗ 𝑒
[𝑄]𝑚∗𝑉𝑠𝑝ℎ𝑒𝑟𝑒  Equation 10 
in which Vsphere is the volume of the sphere of action. (128) 
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2.6.5) Time-resolved lifetime measurements 
Lifetime measurements are crucial to distinguish between different fluorescence 
quenching mechanisms. The lifetime indicates the time that the probes are available to 
interact with the environment. There are many types of lifetime measurement techniques, 
and here the time-resolved measurements were implemented. More specifically, frequency-
domain measurements were executed. In these, an intensity-modulated light source excites 
the sample with a high frequency and its emission, which is intensity-modulated at the same 
frequency, is delayed in relation to the modulated excitation. That delay is measured as a 
phase angle shift between the excitation and emission and the peak-to-peak height provides 
a measure of the lifetime. This is possible because the emission’s phase shift and 
modulation depend on the light modulation frequency and the relative values of lifetime. 
Experimentally, a wide range of frequencies is used to measure these two parameters, 
providing the frequency response of the sample. The output is the phase angle and the 
modulation plotted versus the selected frequencies; in exponential decays the first 
increases while the second decreases (Figure 9). (128) 
 
 
Figure 9 – Graphic output of a time-resolved frequency-domain lifetime experiment. 
 
For this assay, samples with a fixed concentration of DMPC LUV (500 M) labelled 
with TMA-DPH or DPH and various concentrations of drug (0-100 M) were prepared and 
read, after an incubation period of 30 min at 37 ºC, on a Fluorolog Tau-3 Lifetime System. 
All measurements were made at 37 ºC using Ludox as a reference standard (τ = 0.00 ns). 
Table 6 displays the other experimental parameters used to determine the probes lifetime 
in the absence and presence of diclofenac. 
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Table 6 – Parameters used in time-resolved frequency-domain lifetime measurements. 
Probe TMA-DPH DPH 
λex 359 nm 357 nm 
λem 429 nm 429 nm 
Slits 
Manual = 0.7 mm; 
Excitation monochromator: Entrance = 7.0; Exit = 0.7 
Emission monochromator: Entrance = 7.0; Exit = 7.0 
Modulation frequencies 20-160 MHz 10-150 MHz 
Number of frequencies 10 
Integration time 10 seconds 
 
The resulting data for each sample was fitted to a 2-component model, from which 
4 parameters are retrieved (f1, f2, τ1 and τ2), being afterwards the weighted average (τ) 
calculated. To extract information about the constant of the quenching component, KD, 
τ0/τ − 1 vs [Q]m was plotted and linearly fitted, being τ0 and  τ  the lifetime of the probes in 
the absence and presence of diclofenac, respectively. 
 
2.7) Lipid phase transition 
The lipid composition – degree of saturation, size of the fatty acid chains and 
cholesterol content – and temperature determine the physical state and organization of 
molecules within a phospholipid bilayer. With increasing temperatures, phospholipid 
bilayers present different physical states, from crystalline phases (highly ordered) to fluid 
phases (disordered) (Figure 10). Below the main phase transition temperature (Tm) the 
bilayer is in the gel phase, which consists in a solid ordered state. Above Tm, the bilayer is 
in a more disordered and fluid state, which is the fluid phase (Figure 10). This gel-to-liquid 
transition temperature will vary according to the bilayer hydrocarbon chains length and 
chemical structure and also on the structure of the lipid polar headgroups. Indeed, the 
presence of unsaturated acyl chains and of smaller acyl chains decreases Tm of 
phospholipid bilayers. (70) 
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Figure 10 – Representation of a lipid phase transition, from the most organized phase (crystalline) to the 
fluid phase (above the main phase transition temperature, Tm), known to be the natural state of cell membranes. 
 
The fluid phase generally represents the natural state of cell membranes; however, 
more rigid domains can be found in plasma membranes. (70, 129) In order to understand 
how diclofenac affects the lipid phase transition, steady-state fluorescence anisotropy was 
resourced to evaluate the diclofenac’s effect on the DMPC main phase transition 
parameters, including Tm and cooperativity (B). The latter indicates how well the lipids 
cooperate when the phase transition occurs. This technique has proven to be adequate for 
the study of liposome membrane fluidity and to assess the interactions between lipid 
membranes and compounds with high membrane affinity. (130) 
 
2.7.1) Fluorescence anisotropy 
Fluorescence anisotropy enables the molecular dynamics study of fluorescent 
solutes. To do this, polarized light is used to excite the sample and subsequently its 
emission is likewise polarized. Anisotropy describes the extent of the emission polarization 
by providing the average angular displacement of the fluorophore (between the absorption 
and emission of a photon), which depends on its rate and extent of rotational diffusion during 
the excited state lifetime. In turn, the rotational diffusion is conditioned by the solvent 
viscosity and the shape of the rotating molecule; in this case, this parameter will depend on 
the lipid bilayer physical state. (128) Anisotropy (r) is given by the following equation: 
𝑟 =
𝐼∥−𝐼⊥
𝐼∥−2𝐼⊥
    Equation 11 
I∥ represents the intensity of the emission polarizer oriented parallel to the direction 
of the polarized excitation and I⊥ is attributed to the observed intensity when the polarizer is 
perpendicular to the excitation. (128) 
Similarly to fluorescence quenching studies, TMA-DPH or DPH labelled DMPC LUV 
(500 µM) in the absence and presence of diclofenac (0, 40 and 80 M) were prepared. After 
the incubation period at 37 ºC, temperature-dependent scans were traced with data 
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collection for every 2 ºC. The used equipment was a Jasco FP-6500 spectrofluorometer 
(Great Dunmow, UK) – equipped with two polarizers in the paths for excitation and emission 
using the L-format method – coupled to a Jasco ADP 303T temperature controller (Great 
Dunmow, UK). Experimental parameters are listed in Table 7. 
 
Table 7 – Parameters used in fluorescence anisotropy for the study of the lipid phase transition. 
Probe TMA-DPH DPH 
Temperature range 10 ºC – 40 ºC 
λex 359 nm 357 nm 
λem 429 nm 429 nm 
Gain 500 V 
Slits 3 nm 
 
Data of anisotropy as a function of temperature were fitted according to: 
𝑟𝑠 =  𝑟𝑠1 +  𝑝1 ∗ 𝑇 +
𝑟𝑠2−𝑟𝑠1+𝑝2∗𝑇− 𝑝1∗𝑇
1+10
𝐵∗(
1
𝑇
−
1
𝑇𝑚
)
  Equation 12 
where rs is the anisotropy, p1 and p2 are the slopes of the linear fits to the data before 
and after the phase transition region (respectively), and rs1 and rs2 are the corresponding ‘y’ 
intercepts. From here both B and Tm were retrieved. 
 
2.8) Drug effect on membrane fluidity 
Besides evaluating the influence of the drug on the lipid phase transition, it is also 
necessary to understand if the membrane fluidity is modified, at a specific physical state, 
with increasing concentrations of drug. Indeed, membrane fluidity comprises different types 
of mobility of membrane components, which are related to the order (phospholipids packing) 
and the microviscosity of phospholipids. The latter is related to the anisotropic movement 
of lipids (lateral and transverse diffusion). (131) Alterations in the membrane fluidity can 
influence proteins function and, thus, their monitoring can contribute to explain some of the 
NSAID therapeutic and toxic effects. 
 
2.8.1) Fluorescence anisotropy 
To study diclofenac’s effect on membrane fluidity, samples with a fixed 
concentration of DMPC (500 M) labelled with DPH or TMA-DPH and several drug 
concentrations (0- 100 M) were prepared and the probes’ anisotropy was measured at 10 
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ºC and 37 ºC after a previous incubation period of 30 min at the same temperature. The 
used equipment was a Jasco FP-6500 spectrofluorometer (Great Dunmow, UK) – equipped 
with two polarizers in the paths for excitation and emission using the L-format method – 
coupled to a Jasco ADP 303T temperature controller (Great Dunmow, UK).  Experimental 
parameters are detailed in Table 8. 
 
Table 8 – Parameters used in fluorescence anisotropy to assess membrane fluidity. 
Probe TMA-DPH DPH 
Temperature range 10 ºC and 37 ºC 
λex 359 nm 357 nm 
λem 429 nm 429 nm 
Gain 400 - 500 V 
Slits 3 nm 
 
Anisotropy data can be influenced by the probe itself, as increasing concentrations 
of drug may alter the fluorophore excited state lifetime, resulting in variations on anisotropy 
values which do not reflect alterations on membrane microviscosity. (132) So, in order to 
eliminate the drug effect on the fluorophore excited state lifetime, anisotropy values are 
corrected according to Equation 13. 
𝑟′ =  
𝜃0+ 𝜏0
𝜃0+ 𝜏
∗  𝑟𝑠𝑠0     Equation 13 
r’ represent the corrected anisotropy values, while rss0 is the experimental 
anisotropy value in the absence of drug. τ0 and τ correspond to the lifetime of the 
fluorophore in the membrane in the absence and presence of the drug, respectively. 𝜃0 is 
the probe rotational correlation time in the absence of drug. (119) 
The probes rotational correlation time is dependent on membrane lipid composition, 
temperature and pH and thus, it should be determined for the exact same conditions (lipid, 
temperature and pH) used in fluorescence anisotropy measurements. However, it was not 
possible to experimentally determine this parameter, since the required equipment to 
perform time dependent anisotropy measurements was not available. Therefore, reported 
values found in literature for both TMA-DPH and DPH were used. As it was not possible to 
find experimental values for lower pH than physiological pH, the same value was assumed 
for all pH studied in this work. Moreover, values reported for TMA-DPH and DPH labelled 
DMPC LUV at 15 ºC and 40 ºC were assumed to be similar to those obtained at 10 ºC and 
37 ºC, respectively. The employed 𝜃0  for TMA-DPH and DPH at 10 and 37 ºC are presented 
in Table 9. 
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Table 9 – TMA-DPH and DPH rotational correlation times in DMPC bilayers. Values taken from (133). 
 TMA-DPH DPH 
10ºC ~ 4.0 ns ~ 4.6 ns 
37ºC ~ 1.5 ns ~ 2.0 ns 
 
2.9) Drug effect on liposome permeability 
The cellular membrane permeability is an important property that determines the 
function of the membrane and can disturb the equilibrium between the intracellular and 
extracellular environments when altered. Since NSAID are known to interact with lipid 
membranes, their association to bilayers may affect this property.  
 
2.9.1) Carboxyfluorescein leakage assay 
There are several methods to study the liposomal permeability and a variety of 
assays makes use of the self-quenching capacities of fluorophores, such as calcein and 
carboxyfluorescein. Basically, these fluorophores can be entrapped in liposomes at high 
concentration which are self-quenched. If the drug alters membrane permeability and 
leakage occurs, the fluorophore leaves the liposome and ends up diluted in the external 
aqueous environment, hence gaining fluorescence. The more drug-induced leakage, the 
more intense will the fluorescence signal be. (129) With carboxyfluorescein, the molecule 
chosen for this work, it has been verified that its encapsulation results in about 98% of self-
quenching – the phenomena is explained by the formation of a dimer that is non-fluorescent. 
(134) 
To assess the liposome permeability, EPC films (25 mM) were hydrated with a 
carboxyfluorescein aqueous solution (50 mM). In order to obtain the carboxyfluorescein-
loaded liposomes, the free fluorophore was separated from the liposomes using a size-
exclusion chromatography. The chromatographic column was prepared with Sephadex G-
25 medium and hydrated with Tris HCl buffer (10 mM, pH 8.0) containing 300 mM of NaCl. 
(135) The separation was performed at room temperature.  
After the separation of the liposomes and the free fluorophore, the liposomal fraction 
was collected and the most concentrated fraction was used to prepare samples with 
different concentrations of diclofenac (0 to 200 µM). After a 30 min incubation at 37 ºC, the 
samples’ fluorescence intensity was read in a Cytation 3 imaging reader (Biotek 
Instruments, Inc.) also at 37 ºC using λex = 490 nm and λem = 519 nm. (136) The addition of 
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polidocanol 10% (V/V), which destroys the liposomes, allowed to determine the maximum 
fluorescence intensity of the samples. Data were analysed in terms of leakage percentage 
though the following calculation: 
% 𝐿𝑒𝑎𝑘𝑎𝑔𝑒 =
𝐼𝑠−𝐼0
𝐼𝑇−𝐼0
∗ 100  Equation 14 
Where I0 is the initial fluorescence intensity (samples without drug), Is is the sample 
fluorescence and IT is the signal obtained after polidocanol addition. (135) 
Additionally, the determination of the phospholipid concentration of the liposomal 
fraction collected from size-exclusion chromatography was executed, since this 
chromatographic process highly dilutes the initial concentration of phospholipids. This 
determination was performed through a colorimetric method that quantifies inorganic 
phosphate. (135) Aliquots of the collected liposomal fractions were added to glass tubes 
and the solvent was completed evaporated at 120 ºC. Perchloric acid 70 % (0.4 mL) was 
added and the glass tubes were covered with glass marbles and kept at 180 ºC in bath of 
paraffin oil for 1 h. After cooling, 1 mL of water and 0.4 mL of ammonium molibdate 1.25 % 
(w/v) were added to the tubes and vortexed. The addition of 0.4 mL of 3 % ascorbic acid 
(w/v) and immediate vortexing followed. Next, the tubes were maintained in a water bath at 
100 °C for 5 min and then immediately cooled in running water. Finally, absorbance was 
read at 797 nm and the phosphate concentration was calculated based on the standard 
curve made of 0.001 M of monopotassium phosphate solution. This curve was obtained by 
pipetting different volumes of the monopotassium phosphate solution into glass tubes, 
which were treated exactly the same way as the glass tubes containing the liposomal 
fractions aliquots.  
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3. Results and Discussion 
3.1) Diclofenac’s membrane partition 
The partition coefficient (Kp) of diclofenac in DMPC liposomes, used as a membrane 
model system in this work, was determined through derivative spectrophotometry. An 
example of the gathered absorbance spectra and subsequent data analysis is shown in 
Figure 11. From the absorbance spectra of diclofenac experimentally obtained for 
increasing concentrations of DMPC LUV (Figure 11 – A), the third derivative spectra was 
calculated (Figure 11 – B). Using maximum values from that spectra (~286 nm), data was 
plotted against the respective DMPC concentration (Figure 11 – C, black dots) and the 
resulting curve was fitted to Equation 3 (Figure 11 – C, red line). From that fitting, Kp values 
were retrieved. 
 
 
Figure 11 – Absorbance spectra (A) and third derivative spectra (B) of diclofenac with increasing 
concentrations of DMPC LUV at pH 5. The fitting of Equation 3 to maximum values of the third derivative spectra 
(orange circle indicates maximum region) versus respective DMPC concentration is displayed in curve C. 
 
The existence of a spectral bathochromic shift indicates a change in the polarity of 
the environment. This shift can be observed both on the original absorbance spectra (Figure 
11 – A) and on the third derivative spectra with increasing concentrations of DMPC LUV 
(Figure 11 – B), thereby proving that the drug is partitioning from the aqueous to the lipid 
phase. Additionally, the third derivative spectra show distinct isosbestic points (Figure 11 – 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
43 
 
B), which confirms the complete elimination of the background signals arising from the light 
scattered by liposomes and also indicates the existence of drug molecules at both aqueous 
and lipid media. 
Diclofenac’s partition coefficients were estimated for the three pH conditions under 
analysis, as presented in Table 10. The Kp that results from the above mentioned fitting is 
in L/mol. However, in order to compare values with other studies in the literature, the Kp 
calculation in the logarithmic scale is required. The presented values of log(D) – pH-
dependent property – derive from the application of the logarithm to the dimensionless Kp, 
which is calculated by considering the lipid molar volume (Vm) (Equation 15) – known to be 
approximately 0.66 L/mol for DMPC. (137)  
log (𝐷) = 𝑙𝑜𝑔10(
𝐾𝑝 
𝑉𝑚
)   Equation 15 
From Table 10 it is possible to verify that diclofenac’s Kp varies inversely with pH. 
This means that the drug will have a greater affinity to the liposomes in more acidic 
environments. The Kp at pH 3.0 is more than 4 times superior to the Kp at pH 7.4. Since the 
drug molecule has a pKa of 3.97 (84), its carboxylic acid will be deprotonated and negatively 
charged at physiological pH. Contrastingly, a great percentage of drug molecules (~ 90 %) 
will have the carboxylic acid protonated at pH 3.0. Therefore, the higher Kp at lower pH 
reflects the greater affinity of the protonated and neutral form of diclofenac to partition in the 
DMPC LUV. Accordingly, at pH 5.0 a mixture of drug molecules in both ionization states 
coexist, so the overall Kp value comprises both partitioning of the protonated and 
deprotonated forms of diclofenac.  
 
Table 10 – Partition coefficients (M-1 and logarithmic scale) of diclofenac at three pH conditions and 37 
ºC determined by derivative spectrophotometry. The displayed values are the mean and standard-deviation of 
at least three independent assays. 
pH Kp (M-1) Log(D) 
7.4 2036 ± 142 3.49 ± 0.03 
5.0 3665 ± 561 3.74 ± 0.07 
3.0 8958 ± 1520 4.13 ± 0.07 
 
In fact, the dependence of the Kp on the ionization state of the drug molecules was 
already demonstrated for other NSAID. Taking indomethacin and acemetacin as examples, 
since both have pKa close to 4, partitioning studies also reported a higher partition 
coefficient at pH 5.0 than at pH 7.4. (79, 80) The same applies to the particular case of 
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diclofenac. Its partition coefficients at pH 7.4 and 3.0 determined by Ferreira et al. showed 
the same tendency for the drug’s affinity to the liposomes. Although results are comparable 
for physiological pH (Kp = 1100 ± 100), the higher partition at pH 3.0 (Kp = 26000 ± 3000) is 
probably explained by the use of a more fluid membrane model (EPC LUV). (84) Moreover, 
diclofenac’s partition was first estimated from the conventional octanol/water system and 
the reported log(P) value was 4.40. (138) The partition coefficient measured in the 
octanol/water system only takes into account hydrophobic interactions and does not 
consider any electrostatic interactions and/or hydrogen bonds that may occur between 
compounds and membranes. (139)  Therefore, and as expected, this log(P) is close to 
log(D) gathered at pH 3.0, since the majority of molecules are protonated and hydrophobic 
interactions will drive the partitioning of diclofenac with DMPC bilayers. In contrast, 
electrostatic interactions may be greatly relevant for higher pH, where charged molecules 
are present, justifying the discrepancy of the reported log(P) with the experimentally 
obtained log(D). 
 
3.2) Membrane binding of diclofenac 
Membrane-binding assays were performed to obtain evidence on diclofenac 
possible interaction with the membrane’s surface. A fluorescence titration technique, using 
the anionic probe ANS, was performed in the absence and presence of the drug to evaluate 
a competition mechanism between diclofenac and ANS for the same binding sites at the 
DMPC bilayer surface. The measured fluorescence intensities, related to the amount of 
ANS electrostatically bound to the phospholipids headgroups, were plotted against ANS 
concentrations resulting in the binding isotherms presented in Figure 12. 
Visually, it is possible to perceive that the drug has practically no influence of the 
probe binding to the liposome surface at physiological pH (Figure 12 – A). However, a 
decrease of the fluorescence intensity dependent on diclofenac concentrations is noticeable 
at pH 5.0 (Figure 12 – B), immediately indicating that the drug is influencing the probe-
membrane binding. That tendency is even more accentuated at pH 3.0 (Figure 12 – C), 
which corroborates diclofenac’s greater affinity to the membrane in more acidic 
environments. 
The fitting of the curves displayed in Figure 12 to Equation 4 allowed the estimation 
of the binding constant (K), the binding process cooperativity (b) and the maximum 
fluorescence intensity (Cmax). These values are presented in Table 11 for all studied 
conditions. No relevant differences were found in any parameters at pH 7.4, thereby 
confirming that the deprotonated form of diclofenac, at least in the studied concentrations, 
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does not compete with ANS to bind to the membrane surface. On the other hand, Cmax 
decreases for pH 5.0 and even more for pH 3.0 in the presence of the drug. This proves 
that, with increasing concentrations of diclofenac, there are less ANS molecules binding to 
the membrane. So, ANS and the drug are competing for the same binding sites at the 
membrane surface. Despite hindering the access of ANS to the membrane by a competition 
mechanism, diclofenac does not alter the binding rate of ANS seen that no major changes 
in K and b were observed. 
 
 
Figure 12 – ANS membrane binding isotherms (fluorescence intensity vs [ANS]), obtained with three drug 
concentrations (0 µM – black squares, 40 µM – red dots, 80 µM – green triangles) and for three pH conditions – 
pH 7.4 (A), pH 5.0 (B) and pH 3.0 (C) – at 37 ºC. 
 
Since ANS is a negatively charged probe, it establishes electrostatic interactions 
with the bilayer headgroups. (140) The replacement of the probe by diclofenac at the 
liposome surface could be firstly assumed to occur by the same type of interactions. 
However, at pH 7.4, in which diclofenac molecules are deprotonated and negatively 
charged, no competition was verified. This result may be related to the lower Kp and 
subsequent smaller membrane concentrations obtained at this pH. Diclofenac-membrane 
binding is much more relevant for lower pH, when the drug molecules become protonated 
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and neutral. Thus, hydrophobic interactions and/or hydrogen bonds may drive the drug-
membrane binding and diclofenac may locate within the headgroup region of 
phosphatidylcholines, thereby preventing ANS-membrane binding. 
 
Table 11 – ANS membrane-binding parameters – binding constant (K), cooperativity (b) and maximum 
fluorescence intensity (Cmax) – obtained with increasing concentrations of diclofenac, under three pH conditions 
and at 37 ºC. Values are presented as mean and standard deviation of two independent assays. 
pH 
[Diclofenac] 
(M) 
[Diclofenac]m 
(M) 
K b Cmax 
7.4 
0 0 0.073 ± 0.001 1.33 ± 0.01 936 ± 43 
4.0 x 10-4 4.9 x 10-2 0.068 ± 0.003 1.25 ± 0.01 976 ± 6 
8.0 x 10-4 9.7 x 10-2 0.074 ± 0.002 1.33 ± 0.01 938 ± 17 
5.0 
0 0 0.069 ± 0.001 1.29 ± 0.05 1005 ± 50 
4.0 x 10-4 6.6 x 10-2 0.069 ± 0.003 1.25 ± 0.02 916 ± 34 
8.0 x 10-4 1.3 x 10-1 0.067 ± 0.001 1.27 ± 0.05 857 ± 59 
3.0 
0 0 0.08 ± 0.01 1.40 ± 0.06 1049 ± 86 
4 x 10-4 9.0 x 10-2 0.076 ± 0.004 1.34 ± 0.03 880 ± 59 
8 x 10-4 1.8 x 10-1 0.074 ± 0.006 1.36 ± 0.01 747 ± 63 
 
No previous studies in the literature have performed a similar assay with diclofenac. 
Nevertheless, the assessment of diclofenac binding to human polymorphonuclear 
neutrophils (PMN) by Perianin et al. has effectively shown its ability to compete for the cell’s 
high-affinity binding sites of the chemotactic factor N-formyl-methionyl-leucyl-phenylalanine 
(FMLP), demonstrating diclofenac’s tendency to bind to PMN (141) and therefore providing 
evidence for the drug’s affinity to cellular membranes. Also, some works have investigated 
diclofenac’s interaction with mitochondria and have proven its ability to induce mitochondrial 
permeabilization transition (142), which can hint at a possible binding between diclofenac 
and the mitochondria membrane. 
In this context, nimesulide binding to a mitochondrial membrane model revealed that 
this NSAID has affinity for mitochondrial membranes. (103) Additionally, isothermal titration 
calorimetry was used to study the binding of indomethacin and acemetacin with EPC 
liposomes, allowing to verify that the membrane’s biophysical properties were modified 
when saturation with the drugs was attained – this apparently takes places at a lipid/drug 
ratio of 12:1 for acemetacin and 17:1 for indomethacin. (143) 
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3.3) Membrane location of diclofenac 
To assess the membrane location of diclofenac, the drug’s quenching ability was 
studied by performing fluorescence quenching assays with the fluorescent probes TMA-
DPH and DPH that have well-known membrane location (Figure 8). In order to identify the 
type of quenching mechanism occurring between diclofenac and each probe, experiments 
were complemented with time-resolved lifetime measurements. An example of the 
quenching and lifetime results is displayed in Figure 13 for each probe. 
 
Figure 13 – Quenching and lifetime results obtained with TMA-DPH (A) and DPH (B) for pH 3.0 at 37ºC. 
Black squares represent data retrieved from fluorescence quenching assays (I0/I -1) and red dots represent lifetime 
data (0/ – 1). 
 
From the information obtained with both assays it is possible to conclude on how 
the probe is quenched. In the case of DPH, a straightforward analysis was made since the 
Stern-Volmer constant (Ksv), retrieved from the linear fitting of the data gathered in 
fluorescence quenching assays, differed from the constant estimated for the dynamic 
quenching (KD), obtained by time-resolved lifetime data (Figure 13 – B). Thus, it was verified 
that the quenching phenomena resulted from the contribution of both dynamic and static 
quenching. The static component was calculated as being the difference between Ksv and 
KD. 
For TMA-DPH, fluorescence quenching data did not present a linear profile (Figure 
13 – A). Thus, its analysis would firstly appear to be adequate by considering the two models 
that describe positive deviations from the linear Stern-Volmer plots (Equations 9 and 10). 
Yet, neither the combined dynamic and static quenching nor the sphere of action models 
described the non-linear profile of the curves. In fact, a closer look shows that there is, in 
fact, a negative deviation for low diclofenac concentrations (0 – 0.10 M) and not a positive 
deviation for higher concentrations, since a linear profile is obtained for diclofenac 
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concentrations over 0.10 M. This negative deviation may be related to the rigidifying effect 
of diclofenac verified in TMA-DPH labelled DMPC liposomes, at those same concentrations 
and at 37 ºC, that was later observed with the evaluation of diclofenac’s effects on 
membrane fluidity by fluorescence anisotropy measurements (section 3.5). Indeed, an 
increase of membrane order at the region where TMA-DPH inserts within the membrane 
leads to an increment of the probe fluorescence intensity, which overcomes the quenching 
ability of diclofenac at low concentrations, leading to an overall decrease of I0/I. Since, with 
exception to low concentrations, fluorescence quenching and time-resolved lifetime data 
obtained with TMA-DPH labelled liposomes are nearly overlapping (Figure 13 – A) for all 
studied conditions (data not shown), a purely dynamic quenching mechanism was assumed 
for the interaction of diclofenac with this probe. Hence, Ksv were considered to be equal to 
KD values. The quenching constants obtained by fitting the curves to the adequate 
quenching model are presented in Table 12. 
Importantly, the drug location is assessed by analysing the drug’s extent of 
quenching with each probe, which is given by the bimolecular quenching rate constant (Kq). 
This value provides the efficiency of quenching and, since it is obtained from Ksv divided by 
0, it allows to compare the extent of quenching for different probes by eliminating the 
influence of the intrinsic lifetime of each probe. Kq values are presented in Table 12. The 
typical values of Kq for diffusion-controlled quenching are near 1x1010 M-1s-1. However, 
smaller values can be obtained when steric shielding of the fluorophore occurs or if the drug 
has a low quenching efficiency. Contrastingly, higher values may be obtained if some type 
of binding interaction between the drug and the probe occurs. (128) 
 
Table 12 – Quenching constant (Ksv), with respective static (KS) and dynamic (KD) components 
estimated after selecting the adequate quenching model, and bimolecular quenching rate constant (Kq). Values 
of Ksv and KD correspond to linear fitting slopes of fluorescence quenching and lifetime assays and respective 
associated errors. For TMA-DPH Ksv values (*) were assumed to be equal to KD. 
Probe 
Quenching 
Model 
pH Ksv (M-1) KS (M-1) KD (M-1) 
Kq x 108 
(M-1s-1) 
T
M
A
-
D
P
H
 Dynamic 
quenching 
7.4 1.1 ± 0.1* - 1.1 ± 0.1 2.54 ± 0.03 
5.0 1.15 ± 0.05* - 1.15 ± 0.05 2.58 ± 0.02 
3.0 1.1 ± 0.1* - 1.1 ± 0.1 2.29 ± 0.02 
D
P
H
 
Dynamic 
and static 
quenching 
7.4 1.28 ± 0.06 0.6 ± 0.1 0.65 ± 0.09 1.52 ± 0.01 
5.0 0.46 ± 0.07 0.26 ± 0.07 0.20 ± 0.02 0.55 ± 0.01 
3.0 0.57 ± 0.05 0.34 ± 0.06 0.23 ± 0.04 0.66 ± 0.01 
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The analysis of Table 12 and Figure 14, where the quenching data obtained with 
both probes at the three pH conditions are presented, shows that diclofenac has a low 
quenching efficiency. Indeed, Kq values obtained for both probes are lower than the 
diffusion-controlled value confirming the previously stated. Although diclofenac possesses 
two relevant chemical groups that are effective quenchers (chlorine and aromatic amine) 
(128), the drug molecule orientation in the bilayer may limit its ability to quench the 
fluorescent probes. This is a possible explanation for the small extent of quenching hereby 
obtained for diclofenac. 
 
Figure 14 – Fluorescence quenching (I0/I – 1) plots for TMA-DPH (red dots) and DPH (green triangles) 
as a function of diclofenac’s membrane concentration obtained at three pH conditions – pH 7.4 (A), pH 5.0 (B) and 
pH 3.0 (C) – at 37ºC. 
 
Kq values are suitable for the direct comparison of the diclofenac’s quenching 
efficiency for both probes and demonstrate that the extent of quenching is clearly higher for 
TMA-DPH (Table 12). Therefore, this experiment provides evidence that diclofenac may be 
located near the polar headgroup region of the phospholipid bilayer, since it exerts a greater 
quenching effect in TMA-DPH, which is known to anchor to phospholipids headgroups. This 
finding is in agreement with the results obtained when studying the diclofenac-membrane 
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binding (section 3.2), which showed the ability of diclofenac to occupy the binding sites of 
ANS at the membrane surface. Nevertheless, the drug’s small quenching of DPH also 
indicates that part of the molecules reaches the lipid acyl chains, where DPH is usually 
located. Interestingly, the quenching efficacy of TMA-DPH does not depend on the drug’s 
ionization state or medium pH (Table 12), which indicates that both protonated and 
deprotonated molecules will rather locate at the headgroup region of phospholipids. 
Previous experimental studies coherently pointed out that diclofenac locates nearby 
the polar headgroups of the membrane bilayer and suggested that interactions occurred by 
electrostatic adsorption with the zwitterionic headgroups of phosphatidylcholine. In fact, this 
electrostatic adsorption may drive the diclofenac-membrane interaction when the drug is 
deprotonated and negatively charged but when the drug molecules are protonated and 
neutral hydrophobic interactions and/or hydrogen bonds must take place. The non-polar 
side of the drug molecule is thought to remain in the neighbourhood of the hydrophobic acyl 
chains of the phospholipids. (84, 99, 118) 
Both ibuprofen and naproxen were found to locate preferentially in the phosphate 
region (118) and clonixin’s membrane location assessment with several fatty acid probes 
similarly indicates that the drug is positioned in the external part of the membrane. (83) It 
has been reported that NSAID with neutral charge will tend to establish hydrophobic 
interactions with the phosphoslipids’ acyl chains and thereby insert deeper into the bilayer, 
while negatively charged NSAID preferentially establish electrostatic interaction with the 
phospholipids’ headgroup region. (144) However, the assumption that a neutral charged 
NSAID inserts deeper into the bilayer was not verified here with diclofenac. 
  
3.4) Diclofenac’s effects on lipid phase transition 
The diclofenac’s effect on the main phase transition parameters of DMPC LUV was 
evaluated by fluorescence anisotropy measurements in a range of temperatures (10-40 ºC). 
The output of these assays was data with a sigmoidal profile in which the initial portion with 
higher anisotropy values (smaller probe rotation) correspond to the lipid’s gel phase and the 
final portion to its fluid phase; the abrupt drop of anisotropy corresponds to the occurrence 
of the phase transition (Figure 15). The red line in Figure 15 represents the fitting of the 
data to Equation 12, from which both the temperature (Tm) and the cooperativity (B) of the 
lipid main phase transition were retrieved. 
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Figure 15 – Fluorescence anisotropy of TMA-DPH in DMPC liposomes as a function of temperature at 
pH 7.4. The red continuous line is the best fitted curve to Equation 12. 
 
First and foremost, close values for DMPC Tm reported in the literature (24 ºC) (145) 
were obtained (Table 13). Although values in the absence of the drug are concordant with 
both probes at pH 7.4 and pH 5.0 (~24.7 ºC), superior Tm were obtained at pH 3.0. Such 
increase may be related to the partial protonation of the phosphate groups of DMPC at pH 
3.0, which alters the overall electrostatic properties of DMPC bilayers and may lead to an 
increase of DMPC packing density, thus explaining the superior Tm obtained for pH 3.0. 
Indeed, zwitterionic/cationic binary lipid mixtures, for instance DMPC/DMTAP (dimirystoyl-
trimethylammonium-propane), present higher Tm values than that obtained with DMPC 
alone explained by a rearrangement of lipids packing by the presence of cationic lipids. 
(146) 
From a straightforward observation of the sigmoidal profiles obtained for TMA-DPH 
labelled DMPC LUV in the absence and presence of diclofenac in different concentrations 
and under the three pH conditions in analysis (Figure 16), it is evident that the drug’s effect 
is much more relevant for lower pH. The gathered Tm and B values for all the studied 
conditions (Table 13) confirm such observation. These values show that both the 
temperature and cooperativity of the lipid main phase transition decrease with increasing 
concentrations of diclofenac. This trend is much more noticeable as the pH lowers, 
reflecting the greater affinity (higher Kp) of diclofenac to the phospholipid bilayer at lower 
pH and the subsequent higher membrane concentration of drug at these pH. So, the 
analysis of Table 13 allows to conclude that diclofenac’s effect on the DMPC phase 
transition parameters is not only dependent on the drug’s membrane concentration, but also 
on its ionization state. Indeed, regarding TMA-DPH results, the effect of 9.0 x 10-2 M of the 
protonated form of diclofenac (pH 3.0) is much more pronounced than the effect of a similar 
T
m
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membrane concentration (9.7 x 10-2 M) of diclofenac at pH 7.4. Thus, these two molecular 
forms must interact with DMPC bilayers differently. 
 
 
Figure 16 – Steady-state anisotropy of TMA-DPH labelled DMPC LUV as a function of temperature under 
three diclofenac concentrations (0 µM – black squares, 40 µM – red dots, 80 µM – blue triangles) at three pH 
conditions (7.4 – A, 5.0 – B, 3.0 – C). 
 
Importantly, for high drug concentrations at pH 3.0 (Figure 16 – C), the sigmoid 
profile gets broader and this is related to the notorious decrease of the lipid’s cooperativity 
in the phase transition (Table 13). This event is also evident when looking at Tm values 
which, unlike what occurs in other conditions, are higher for 8.0 x 10-5 M of diclofenac than 
for 4.0 x 10-4 M at pH 3.0 for both probes. Thus, the Tm in these conditions is not necessarily 
a value, but a range of values in which the phase transition is occurring – the onset 
temperature at which the phase transition starts occurring is in fact lower as the drug 
concentration increases (accordingly to the observed tendency with other pH) but the Tm 
value retrieved from the fitting corresponds to an intermediate value of this temperature 
range. 
Furthermore, comparing the results obtained with the two probes, it possible to see 
that, although tendencies are similar, there is a more pronounced effect when TMA-DPH is 
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labelling the DMPC LUV. This is explained, firstly, by the fact the phospholipid bilayers have 
a fluidity gradient in which their core is more disordered and therefore less subjected to 
alterations. (147) Since TMA-DPH locates near the phospholipids headgroups, which 
consist in the area with higher level of organization, the drug presence leads to a greater 
perturbation. Additionally, considering the previous results obtained for membrane location, 
diclofenac has shown to influence TMA-DPH in a greater extent which also justifies a 
greater effect on the membrane biophysical properties in this region. 
 
Table 13 – DMPC phase transition parameters (Tm and B) in the absence and presence of diclofenac 
under three pH conditions and for 2 different probes (TMA-DPH and DPH). The presented values correspond 
to means and standard-deviations of at least two independent assays. 
Probe  pH 
[Diclofenac] 
(M) 
[Diclofenac]m 
(M) 
Tm B 
T
M
A
-D
P
H
 
7.4 
0 0 24.71 ± 0.02 358 ± 15 
4.0 x 10-4 4.9 x 10-2 24.49 ± 0.06 284 ± 34 
8.0 x 10-4 9.7 x 10-2 24.13 ± 0.05 223 ± 22 
5.0 
0 0 24.7 ± 0.1 295 ± 34 
4.0 x 10-4 6.6 x 10-2 23.6 ± 0.3 132 ± 8 
8.0 x 10-4 1.3 x 10-1 23.1 ± 0.3 86 ± 2 
3.0 
0 0 25.3 ± 0.5 265 ± 43 
4 x 10-4 9.0 x 10-2 23.4 ± 0.1 91 ± 1 
8 x 10-4 1.8 x 10-1 23.92 ± 0.09 80 ± 7 
D
P
H
 
7.4 
0 0 24.9 ± 0.1 389 ± 16 
4.0 x 10-4 4.9 x 10-2 24.79 ± 0.04 321 ± 32 
8.0 x 10-4 9.7 x 10-2 24.47 ± 0.07 273 ± 17 
5.0 
0 0 24.73 ± 0.03 317 ± 39 
4.0 x 10-4 6.6 x 10-2 23.7 ± 0.2 147 ± 16 
8.0 x 10-4 1.3 x 10-1 23.20 ± 0.09 91 ± 5 
3.0 
0 0 26.04 ± 0.04 288 ± 5 
4 x 10-4 9.0 x 10-2 24.68 ± 0.01 104 ± 7 
8 x 10-4 1.8 x 10-1 24.9 ± 0.8 71 ± 3 
 
A work that used DSC to assess diclofenac effect on the DMPC phase transition 
also showed that the drug lowers its Tm and the lipid’s cooperativity – in this case, this was 
indirectly seen by the broadening of the lipid phase transition peak. Furthermore, it indicates 
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that diclofenac is likely to induce a higher reorganization in the lipid membrane, in 
comparison to other NSAID, since a stronger shift in the Tm  was observed. (118) 
Studies with other NSAID, namely meloxicam, tenoxicam, piroxicam and 
lornoxicam, have proved their ability to lower Tm and broaden the phase transition of DPPC 
in neutral and acidic environments (148). Similar results were obtained with acemetacin and 
indomethacin (86), being in agreement with the actions reported herein for diclofenac. 
 
3.5) Diclofenac’s effect on membrane fluidity 
The influence of diclofenac on DMPC fluidity was assessed by steady-state 
fluorescence anisotropy using TMA-DPH and DPH as fluorescent probes. Importantly, 
experimental anisotropy values (rss) were corrected (r’) to eliminate the drug influence on 
the probes excited lifetime state (Equation 13). Indeed, the difference between rss and r’ 
describes the real variation of anisotropy caused by the drug. Hence, results are presented 
as rss-r’ (Figure 17 – left side) and also expressed according to their fluidizing effect (Figure 
17 – right side), calculated from Equation 16. 
% 𝑓𝑙𝑢𝑖𝑑𝑖𝑛𝑔 𝑒𝑓𝑓𝑒𝑐𝑡 =
𝑟𝑠𝑠−𝑟
′
𝑟0
′ ∗ 100  Equation 16 
Since lower anisotropy values reflect higher membrane fluidity, it is possible to verify 
for both probe a general tendency to fluidify the membrane in the gel phase (Figure 17 – A 
and C). Results with TMA-DPH showed a marked concentration-dependent fluidizing effect 
at both acidic pH in the gel phase (Figure 17 – A) and at pH 3.0 in the fluid phase (Figure 
17 – B). Interestingly, a slight rigidifying effect occurs at 37 ºC for the lowest concentrations 
of diclofenac. Relatively different tendencies were observed with DPH-labelled DMPC LUV. 
While in the gel phase, the drug has a more pronounced fluidizing effect at pH 3.0 (Figure 
17 – C), a rigidizing effect was observed for pH 3.0 and 5.0 at 37 ºC (Figure 17 – D). When 
comparing results obtained with both probes, diclofenac clearly exerts a more pronounced 
fluidizing effect for TMA-DPH labelled liposomes. Once again, the headgroup region of 
DMPC bilayers are more organized and thus, the drug insertion in this region will greatly 
disturb its fluidity. Contrastingly, DPH is located between the acyl chains of DMPC which is 
a more disorganized region of the bilayer than the headgroup region. The opposite effect of 
diclofenac on membrane fluidity verified in the gel and fluid phase may be related to the 
initial organization the bilayer. Indeed, at the gel phase the acyl chains have a higher 
packing density than at the fluid phase. Therefore, the drug penetration may disorganize 
the acyl chains at the gel phase, while it may lead to some rearrangement of the lipid acyl 
chains at the fluid phase, thereby increasing the bilayer rigidity. 
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Figure 17 – Corrected steady-state anisotropy values (rss-r’ – left side) of TMA-DPH (A and B) or DPH (C 
and D) labelled DMPC LUV with increasing concentrations of diclofenac for three pH conditions (pH 7.4 – black 
squares, pH 5.0 – red circles, pH 3.0 green triangles) and at 10 ºC (A and C) and 37 ºC (B and D). At the right side, 
the respective fluidizing effect as a function of diclofenac concentration is presented. 
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A similar study has been performed with diclofenac and reported an increase of the 
rigidity in the phospholipids headgroups of EPC. (84) The same behaviour was observed in 
this study for low concentrations of diclofenac, while higher concentrations caused a 
fluidizing effect on the DMPC headgroups region. This discrepancy may be due to the 
difference on the phospholipids used to prepare the membrane models. Indeed, EPC form 
bilayers with greater fluidity than DMPC due to the presence of unsaturated acyl chains. 
So, the drug insertion may organize EPC bilayers, while disordering DMPC bilayers with 
higher initial order. Yet, both works highlight that diclofenac has a stronger action in the 
headgroups of phospholipids. 
Concerning works with other NSAID, an increase of membrane fluidity in a 
concentration dependent manner has been verified with nimesulide, indomethacin, 
acemetacin (132), meloxicam, lornoxicam (149) and clonixin (83). Altogether, these studies 
provide evidence that NSAID can insert in lipid bilayers, alter their dynamics and possibly 
modify the activity of membrane-bound proteins. 
 
3.6) Diclofenac’s effect on membrane permeability 
A leakage assay using carboxyfluorescein as a fluorophore was performed to 
assess diclofenac’s capacity of altering membrane permeability. When carboxyfluorescein 
is at high concentrations inside the inner aqueous compartment of LUV, its fluorescence is 
self-quenched. If the drug disrupts the bilayer permeability, the dye will be released and 
diluted, and its fluorescence intensity will greatly increase. 
In this context, the first step was the separation of carboxyfluorescein-loaded 
liposomes using a chromatographic column (Figure 18). Since this was performed at room 
temperature, the use of DMPC in these conditions was a hindrance for the success of the 
experiment, since this lipid (Tm ~ 24 ºC) is in the gel phase or even in the phase transition 
temperature at room temperature. For that reason, EPC liposomes were chosen as 
membrane model system, because EPC has a lower Tm and the same polar headgroup of 
DMPC. 
Carboxyfluorescein has four pKa values, meaning that it can be found in five different 
ionization states according to the medium pH. These intrinsic structural changes of the 
molecule alter its spectral response, hence the fluorophore presents different emission and 
absorbance spectra under different pH. (136) Although this assay was performed under the 
three pH conditions selected for this project, the analysis of the results at acidic pH (5.0 and 
3.0) was not possible since the fluorophore suffered molecular alterations and the disruption 
of membrane permeability did not lead to an increase on carboxyfluorescein fluorescence 
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intensity. Consequently, the results presented herein only refer to experiments performed 
at physiological pH. 
 
 
Figure 18 - Carboxyfluorescein-loaded EPC LUV separation through size-exclusion chromatography. A, 
B and C show the progression of the lipid separation from the free carboxyfluorescein. D corresponds to the 
collection of the lipid fraction. 
 
After obtaining carboxyfluorescein-loaded EPC LUVs, different concentrations of 
diclofenac were added and after an incubation period, the fluorescence intensity was 
measured. Experimental data were then adjusted to Equation 14 and the percentage of 
leakage versus the drug/lipid ratio is presented in Figure 19.  
 
Figure 19 – Leakage percentage versus the drug/lipid ratio ([Diclofenac]/[DMPC]). Presented data 
corresponds to the mean value and standard deviation of two experimental replicates. 
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Firstly, a diclofenac effect on membrane permeability was verified since the 
percentage of leakage increases with higher drug/lipid ratios (Figure 19). This effect seems 
to be directly dependent of the drug/lipid ratio until approximately 1.0; from there a saturation 
plateau is apparently reached. The maximum leakage attained with diclofenac in these 
conditions was around 20%, which is a considerable effect in terms of membrane 
permeability. Importantly, as the drug partition indicates a higher affinity to the membrane 
as the pH lowers, it can be predicted that this effect would be more significant for pH 5.0 
and 3.0. In order to obtain results for acidic conditions, a non pH-dependent fluorophore 
must be used. 
There are related works in the literature that evaluated NSAID-induced permeability 
through an identical assay, using calcein as a fluorophore. In 2004, the assessment of 
several NSAID showed an increase of PC liposomes permeability and the authors suggest 
that this effect was related to their cytotoxicity. (98) Despite the attainment of very high 
leakage percentages, the drug/lipid ratio was much higher than 1, which contrasts to the 
drug/lipid ratios used in this work. The study of the effect of indomethacin on phospholipids 
(dilinoleoyl-phosphatidylcholine, DLPC) revealed low releases of calcein (< 5 %). However, 
as the focus of the study was the evaluation of membrane damage in the presence of bile 
contents, the addition of bile acids significantly enhanced the drug effect on membrane 
permeability. (150) A similar result to the one obtained with diclofenac in this work was found 
for nimesulide – 15% leakage at 1:1, with 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
(POPC) as a model membrane. (103) 
Although there are no similar studies in the literature for diclofenac, this drug has 
been previously considered to increase the intestinal mucosa permeability (151) and to 
induce the mitochondria permeability transition (142). In fact, the study of diclofenac effect 
on membrane permeability is very relevant because evidence points for these mechanisms 
as possible causes for NSAID-induced enteropathy, since these drugs are able to increase 
intestinal permeability. (152) 
  
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
59 
 
4. Conclusion 
The present work focused on assessing, from a biophysical perspective, 
diclofenac’s interactions with biological membranes, in order to better understand the drugs’ 
COX-independent mechanisms of action and toxicity. 
In concordance to what had been verified with many other NSAID, diclofenac’s 
ionization state revealed to be one of the major influencing factors of the drug behaviour in 
membranes. In fact, this was not only revealed by the higher drug partition in liposomes 
with lower pH, but by other experiments that studied alterations in membrane properties, 
including lipid phase transition and membrane fluidity, in which the drug effect was pH-
dependent and repeatedly more pronounced at pH 3.0.  
Additionally, the assessment of diclofenac’s membrane location through 
fluorescence quenching studies and supported by the membrane binding assay contributed 
for the elucidation of results concerning the modifications of the membrane biophysical 
properties. Membrane location results were concordant with previous studies performed at 
physiological pH, indicating that diclofenac remains near the phospholipid headgroups, 
regardless its ionization state, possibly establishing hydrophobic interactions and/or 
hydrogen bonds when in the protonated state and electrostatic interactions when negatively 
charged molecules are present. Importantly, gathered evidence reveals the ability of the 
drug to disorganize the phospholipid bilayer, since diclofenac is able to decrease the 
temperature and cooperativity of the phospholipid main phase transition; to fluidize the 
membrane headgroup region when present in high concentrations; and to increase 
membrane permeability at physiological pH. 
In the first place, the pH-dependency of diclofenac can be related to drug’s 
therapeutic effect in inflamed cells (pH~5.0), as well as to the frequently verified diclofenac-
induced gastric complications, since the gastric mucosa possesses a pH gradient between 
1.2 (gastric lumen) and 7.4 (epithelial cells). Indeed, COX is a well-known target of 
conventional NSAID and being a membrane protein – located in the endoplasmic reticulum 
or nuclear envelope – it can be indirectly inhibited by diclofenac through modifications of 
membrane lipids properties that modulate the proteins’ activity and function. 
Regarding the most relevant adverse effects of diclofenac – GI and CV – the 
presented findings support some hypothesis to explain its toxicity. Lichtenberger et al. 
suggested the existence of a gastric surface-active phospholipids protective layer, which 
could be disrupted by the action of NSAID. In this line of thought, results obtained for 
diclofenac can corroborate this theory, since the reported modifications of the 
phospholipid’s biophysical properties by diclofenac may facilitate the entrance of noxious 
The contribution of drug-membrane biophysical studies for the development of safer NSAID: the case of diclofenac 
60 
 
agents in the gastric mucosa, contributing for the occurrence of gastric adverse effects. 
Furthermore, the increased intestinal permeability was already identified as a NSAID-
induced enteropathy cause, and this mechanism may be related to cell damage resulting 
from energy depletion. (152) In this sense, findings of increased membrane permeability 
induced by diclofenac can contribute to the explanation of its GI toxicity. Finally, the verified 
diclofenac-induced membrane disturbances can also be related to the occurrence of CV 
adverse effects. There is increasing evidence that the development of CV diseases, 
including hypertension, atherosclerosis and thrombosis, is associated with alterations on 
lipid composition and structure of membranes. (72) Since erythrocytes have been shown to 
be altered in hypertensive subjects – in terms of lipid composition and levels of signalling 
proteins (153), it would be plausible to relate diclofenac’s membrane effects as a cause of 
erythrocytes morphological alterations described by Suwalsky et al. (99), which in turn may 
contribute or increase patient susceptibility to CV adverse effects. 
In sum, this experimental study has provided insights on diclofenac’s effects at the 
membrane level that contribute for the understanding of its biological actions. Importantly, 
the comprehensive description of traditional NSAID effects on membrane biophysical 
properties may accelerate the development of safer NSAID. The comparison of novel drugs’ 
effects on membranes with those caused by traditional NSAID may distinguish the drugs 
with less impact on membranes, indicating the best candidates for clinical use. Also, the 
addition of in vitro studies with model membranes as a preliminary step during drug 
development will decrease its economic and biological costs by reducing the number of 
molecules reaching in vivo evaluations. The in vitro study of NSAID-membrane interactions 
was already on the basis of the rational development of PC-NSAID which appear to be 
better tolerated in the GI tract than traditional NSAID. (20, 22, 23) Therefore, the study of 
NSAID-membrane interactions may contribute for the development and commercialization 
of effective and safer anti-inflammatory drugs in the near future, thereby improving the 
quality of life of NSAID-chronic users.  
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